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Abstract  
Translating biomedical knowledge of biomarkers into clinically relevant devices that could 
be used as diagnostic or monitoring tools for disease management using effective analytical 
techniques is extremely important and still remains a challenge. However, the existing analytical 
methods for real-time protein detection in homogeneous solutions are limited. 
In this research, molecular aptamers were combined with fluorescence techniques and 
electrochemical sensors to provide an easy and efficient method to detect proteins. In a first step, 
two types of high-affinity thrombin-binding aptamers (TBA1 and TBA2) and OPN-R3, an aptamer 
that has been reported to bind specifically to human osteopontin, were labeled with 6-FAM and 
used as molecular recognition probes to conduct ELISA experiments with human thrombin, human 
osteopontin and interferences such as bovine osteopontin and bovine serum albumin. Through non-
linear fitting it was found a dissociation constant value of 1.820 nM and 0.867 nM for TBA1 and 
TBA2, respectively, and 5.65 nM for OPN-R3. This constant, Kd is commonly used to describe 
the affinity between a ligand and a protein i.e. how tightly a ligand binds to a particular protein. An 
Electrophoretic Mobility Shift Assay (EMSA) was also conducted to validate the formation of the 
aptamer:protein complexes, however the results obtained were inconclusive, possibly due to the low 
protein concentrations used. 
The ultimate goal of this work was to develop a voltammetric aptasensor for the detection of 
thrombin, using the aptamer as the detection probe and [Fe(CN)6]4-/3 as the electrochemical active 
redox solution. Appropriate aptamer sequences (TBA1 and TBA2) were designed to enable binding 
to thrombin, and also to include a biotin molecule in the 5’-end for the immobilization step. The 
aptamers were immobilized through the avidin-biotin methodology on screen-printed electrodes 
adequate for electrochemical detection. Thrombin detection was studied using cyclic voltammetry. 
The aptasensor presented a linear response for thrombin concentrations in the range between 0.5 
nM and 50 nM, and a detection limit of 0.025 nM. Furthermore, this aptasensor was found to be 
specific for thrombin. The results gathered in this thesis are promising, suggesting that aptasensors 
constitute an alternative approach for the detection of proteins with biomedical relevance. 
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Resumo  
  O desenvolvimento de dispositivos que constituam ferramentas de diagnóstico e 
monitorização de doenças, fazendo recurso ao conhecimento existente sobre biomarcadores e 
usando técnicas analíticas eficazes, é actualmente uma área de grande interesse e relevância. No 
entanto, as técnicas analíticas disponíveis para a deteção de proteínas em tempo real e em 
soluções homogéneas são ainda limitadas. 
Neste trabalho de investigação, os aptámeros moleculares foram combinados com 
técnicas de fluorescência e sensores eletroquímicos para desenvolver uma abordagem simples e 
eficiente para a deteção de proteínas. Numa primeira etapa, dois tipos de aptámeros de elevada 
afinidade de ligação à trombina (TBA1 e TBA2) e o aptámero OPN-R3, que foi reportado por se ligar 
especificamente a osteopontina humana, foram marcados com 6-FAM e usados como sondas de 
reconhecimento molecular para conduzir ensaios ELISA com trombina e osteopontina humana e 
interferentes como osteopontina bovina e albumina de soro bovina. Através do ajuste não linear dos 
dados foi possível determinar um valor para a constante de dissociação de 1.820 nM e 0.867 nM 
para TBA1 e TBA2, respectivamente, e 5.65 nM para o OPN-R3. Esta constante, Kd é usada para 
descrever a afinidade entre um aptámero e uma proteína, ou seja, saber quão forte é a ligação 
entre o aptámero e a respectiva proteína. Adicionalmente, foram realizados ensaios de mobilidade 
electroforética, a fim de validar a formação do complexo aptámero:proteína, no entanto os 
resultados obtidos foram inconclusivos, possivelmente devido às baixas concentrações de proteína 
usadas. 
O principal objetivo deste trabalho foi desenvolver um aptasensor voltamétrico para a 
deteção de trombina, usando o aptámero como sonda de detecção e [Fe(CN)6]4-/3 como solução 
redox electroquímica. Foram desenhadas sequências de aptámeros marcados com uma molécula 
de biotina na sua extremidade 5’ para auxiliar o passo de imobilização. Estas sequências: TBA1 e 
TBA2 ligam especificamente à trombina. Os aptámeros foram imobilizados usando a metodologia 
da avidina-biotina em eléctrodos desenhados especificamente para a deteção electroquímica. A 
detecção da trombina foi estudada por voltametria cíclica. O aptasensor apresenta uma resposta 
linear para concentrações de trombina na gama entre 0.5 nM e 50 nM, e um limite de detecção de 
0.025 nM. Adicionalmente, verificou-se que o aptasensor é específico para a trombina. Os 
resultados desta tese são bastante promissores, sugerindo que os aptasensores podem constituir 
uma abordagem alternativa para a deteção de proteínas com relevância biomédica. 
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1. Introduction 
Current demands regarding human health have encouraged the development of an 
increasing number of clinical tests. As a result, there is a growing requirement to develop more 
sensitive, reliable, time-efficient and inexpensive methods of analysis (Hong, Li, & Li, 2012). Despite 
the outstanding progresses in the field of biomedicine, substantial challenges remain in translating 
biomedical knowledge on disease markers into clinically relevant devices that could be used as 
diagnostic or monitoring tools for disease management (X. Y. Wang, Gao, Lu, He, & Yin, 2013). 
Progress in the development of consistent malignancy markers is imminent due to the advances in 
genomics and bioinformatics fields that enabled the analysis of great amounts of data through the 
use of less complex procedures involving less wet-lab analysis, and also with a lower requirement 
for qualified and experienced technical staff to conduct the analysis (Opstal-van Winden et al., 
2011; Rodrigues, Teixeira, Schmitt, Paulsson, & Lindmark-Mänsson, 2007). The adoption of high-
throughput methods led to the discovery of many new biomarkers that have been reported for 
prognostic and predictive purposes. However, out of these only a few have made their way into 
clinical routine mainly due to the lack of sufficient validation (Bohunicky & Mousa, 2010). 
A biomarker is an indicator of a biological state or condition which, besides its value for 
diagnosis purposes, can be helpful to evaluate the body reaction to a given treatment (Bohunicky & 
Mousa, 2010; J. Wang, Chen, Jiang, Li, & Wang, 2013). The use of biomarkers to anticipate the 
outlines of the disease has been an emerging issue, especially in the case of cancer for which 
several treatments have been quite successful in the last few years. Biomarkers can also provide 
information on the mechanism underlying the initiation of a disease, and ultimately they constitute  
a powerful tool to precisely define the disease states, as well as to define appropriate treatments 
even for early stages of  diseases (J. Wang et al., 2013). Some of the biomarkers that undergone 
rigorous testing are summarized in Table 1. 
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Table 1 List of biomarkers tested. Adapted from: Polanski & Anderson, 2006; Tothill, 2009; Opstal-van 
Winden et al., 2011 and Bohunicky & Mousa, 2010 
Biomarker Application 
CA15-3 Monitoring marker breast cancer  
CEA Monitoring marker breast cancer 
CA-125 Monitoring marker breast cancer and ovarian cancer 
CA19-9 Monitoring marker pancreatic and gastrointestinal cancer 
Increased serum levels in human breast cancer cases 
AFP Staging marker testis, ovary and liver cancer 
Increased serum levels in human breast cancer cases 
MIF Higher expression in mammary tumors compared to normal tissue 
Increased serum levels in human breast cancer cases 
Prolactin Risk marker for breast cancer 
Leptin Higher expression in mammary tumors compared to normal tissue 
Risk marker for breast cancer 
Differential plasma levels in human breast cancer cases 
OPN Higher in humanized Mouse models for breast cancer 
Increased plasma and serum levels in plasma breast cancer cases 
Increasing expression in mammary tumor tissue and plasma in progressing disease 
Haptoglobin Higher in humanized Mouse models for breast cancer 
Increased serum levels in human breast cancer cases 
PSA Screening and Monitoring marker prostate cancer 
B-type natriuretic peptide Marker of congestive heart failure 
Bladder Tumor Antigen Marker for urothelial carcinoma 
 
The discovery of new biomarkers is a time-consuming and costly task, since it requires the 
systematic separation and identification of biological molecules from complex body fluids (e.g. 
urine, blood) or tissues (Bohunicky & Mousa, 2010; Medley, Bamrungsap, Tan, & Smith, 2011; 
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Phillips, Xu, Xia, Fan, & Tan, 2009). Biomarkers that have been recognized as reliable for disease 
diagnosis and prognosis are listed in several reference cancer databases (e.g. National Centre for 
Biotechnology Information (NCBI), Cancer Research United Kingdom) and these have been 
approved by the FDA (Food and Drug Administration) (Opstal-van Winden et al., 2011; Tothill, 
2009). Moreover, guidelines have also been developed describing the best approach to report the 
discovery of novel tumor markers, in order to guarantee that such studies are clear and easily 
understood in the context of their conclusions (McShane et al., 2005). 
Biomarkers can either be present inside the cancer cells or be extracellular. Besides, they can 
also be of various molecular origins, including DNA (i.e. specific mutation, translocation, 
amplification, and loss of heterozygosity), RNA, or protein (i.e. hormone, antibody, oncogene or 
tumor suppressor)(Bohunicky & Mousa, 2010). Proteins that are selectively overexpressed as the 
result of cancer cells growth have been selected as potential biomarkers for cancer diagnosis 
and/or prognosis. Thus, these proteins can provide the basis for screening techniques, treatment 
options (Medley et al., 2011; Tothill, 2009), metastasis evaluation, and for determining the 
response to pharmacologic intervention (Sadana & Sadana, 2011). 
Several proteins in the blood were indeed found to be related with the presence of breast 
cancer (J. Li et al., 2005; Lord et al., 2007; Mathelin, Cromer, Wendling, Tomasetto, & Rio, 2006). 
Based on the hypothesis that these proteins can be useful biomarkers for the early detection of 
cancer, great efforts have been developed to discover such proteins that are overexpressed in 
patient’s body fluids (Misek & Kim, 2011). 
During the past decade, emerging evidence has refined the value of osteopontin (OPN) as a 
potential biomarker. OPN is an extracellular matrix protein with adhesive properties, that possesses 
a thrombin cleavage site and a cell attachment sequence found in all body fluids as plasma and 
serum (D. X. Cao et al., 2012; Fisher, Torchia, Fohr, Young, & Fedarko, 2001; Higashikawa, 
Eboshida, & Yokosaki, 2007; Ke et al., 2011; Macrì et al., 2009). Current research showed that 
OPN is often overexpressed in human cancers and contributes to regulate tumor growth and 
progression (Rangaswami, Bulbule, & Kundu, 2006; Rittling & Chambers, 2004; Servais et al., 
2011). Increased OPN expression is one of the characteristics often associated with metastatic 
cancer cells (Kadkol et al., 2006; Rudland et al., 2002; P. Y Wai & Kuo, 2004), and it has been 
suggested as a main player in the progression and metastasis of a variety of cancers, including 
breast, liver, prostate and lung (Shojaei et al., 2012; P. Y. Wai & Kuo, 2008; Weber, Lett, & 
Haubein, 2010). Beausoleil and co-workers (2011) demonstrated that the changes in the OPN 
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plasma levels after therapy and over time could be used to monitor the clinical outcome 
(Beausoleil, Schulze, Goodale, Postenka, & Allan, 2011). 
Several recent studies describe the multiple and complex mechanisms in which OPN is 
involved and suggest it’s potential as a biomarker for ovarian (J.-h. Kim et al., 2002; Matsuura, 
Suzuki, & Saito, 2010), bladder urothelial carcinoma (Park et al., 2012), gastric and liver (D. X. Cao 
et al., 2012), and for breast cancer (BC) (Mirza et al., 2008).  
As mentioned, OPN contains two integrin-binding sites and a thrombin cleavage domain located 
in close proximity to each other. When OPN is cleaved at these domains by thrombin, it is 
separated into two approximately equivalent sized pieces, and since thrombin is also often 
overexpressed on the surface of cancer cells, the tumor microenvironment favors the activation of 
thrombin, and therefore the OPN cleavage (Beausoleil et al., 2011). 
Human thrombin, highly specific serine protease, is also a biomarker that plays an important 
role on procoagulant and anticoagulant functions. This protein plays multiple roles in endothelial 
and smooth muscle cell functions, as well as coagulation and hemostasis (P. Wang et al., 2011). It 
is activated by the proteolytic cleavage of its precursor molecule pro-thrombin generation factor Xa 
(W. Z. Xie et al., 2005). Thrombin converts fibrinogen to insoluble fibrin that forms the fibrin gel, 
which is responsible either for some physiological plugs or for the formation of pathological 
thrombus (Neundlinger et al., 2011). The concentration of thrombin in blood varies considerably 
and it can be almost absent in the blood of healthy individuals. Some studies refer that its 
concentration in blood is normally around 0.01 nM (Frense et al., 2013). However, thrombin can 
reach low-micromolar concentrations during the coagulation process, and low levels of thrombin 
can even be generated in the early hemostatic process (Sosic, Meneghello, Cretaio, & Gatto, 2011). 
In addition to its central role in coagulation, thrombin has been reported to induce mitogenesis 
and differentiation in cancer cells (W. Z. Xie et al., 2005); to regulate microvascular permeability 
(Guttridge, 1997); and also to be involved in blood coagulation, incrustation, inflammation and 
pulmonary metastasis (Chiu & Huang, 2009; Lin et al., 2011). Due to its crucial involvement in 
both thrombosis and hemostasis, thrombin is a major target for anticoagulation and cardiovascular 
disease therapy (Paborsky, N. McCurd, C. Griffin, J. Toole, & L. K. Leung, 1993). 
  Thrombotic disorders and their common clinical phenotypes of ischemic stroke, and 
venous thromboembolism cause substantial health care expenditures, morbidity, and mortality 
worldwide. The in vivo detection of thrombin, for example using aptamers, could be a promising 
method to prevent and/or treat these diseases (P. Wang et al., 2011). 
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1.1. Biosensors  
Currently, there is a high demand for convenient methodologies that allow detecting and 
measuring the levels of specific proteins in biological and environmental samples. In general, their 
detection, identification and quantification using conventional techniques, such as molecular assays 
and microbial culture-based tests, can be very complex, expensive and time consuming (Hong et 
al., 2012). 
A biosensor, as per definition of IUPAC, is an integrated receptor-transducer device, which is 
capable of providing bio-recognition processes into measurable signals via a physicochemical 
transducer, with electronic and optical techniques as two major transducers (Shiping   Song, Xu, & 
Fan, 2006; Beate Strehlitz, Nikolaus, & Stoltenburg, 2008). The use of biosensors brings about a 
combination of advantages. First, biosensors are highly sensitive, mainly because biomolecules 
often possess high affinity towards their targets. Second, biological recognition is usually very 
selective, thus it often leads to selective biosensors. Third, arising due to the development of 
modern electronic industry, it has been relatively easy to develop inexpensive, integrated and ready-
to-use biosensor devices. These biological sensors certainly improve the ability to detect molecules 
or pathogens, besides being of particularly usefulness for small clinics and even for point-of care 
analysis (K. M. Song, Lee, & Ban, 2012; Shiping   Song et al., 2006).  
The core design of a biosensor mainly includes three components namely the probe-target 
recognition (that detects the presence or concentration of biological molecules or biological 
structures), the signal transduction (which translates the biochemical interaction into a quantifiable 
physical signal) and the physical readout (Bohunicky & Mousa, 2010; D'Orazio, 2003; J. O. Lee et 
al., 2008), as illustrated in Figure 1. 
  
Figure 1 llustration of a biosensor functioning process. Taken from Bohunicky & Mousa, 2010 
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1.1.1. Biorecognition element - Aptamers 
The biorecognition element is a critical key component of any biosensor. Fortunately, due to 
advances in technology and synthetic chemistry, many biosensor recognition elements used today 
are synthesized in the laboratory for improved stability and reproducibility of the biosensor function. 
Examples of recognition elements include receptor proteins, antigens, antibodies, enzymes, and 
nucleic acids (specifically aptamers) (Bohunicky & Mousa, 2010). 
 Aptamers (from the Latin word “aptus” meaning to fit and the Greek word “meros” 
meaning particle or piece) (Mairal et al., 2008; Mayer, 2009) are artificial nucleic acid ligands 
which can be selected from combinatorial libraries of synthetic nucleic acids, possessing motifs that 
recognize their targets (Hong et al., 2012). These molecules are 20–80 base pair long single-
stranded ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) oligonucleotides which are folded 
into distinct three-dimensional conformations (Kanwar, Roy, & Kanwar, 2011). Binding occurs 
because of their specific and complex three-dimensional shape characterized by loops, hairpins, 
stems, bulges, pseudoknots, triplexes, or quadruplexes. The structure compatibility results in the 
aptamer-target binding by stacking of aromatic rings, van der Waals and electrostatic interactions, 
and hydrogen bonding, or from a mixture of these effects (B. Strehlitz, Reinemann, Linkorn, & 
Stoltenburg, 2011).  
Aptamers are similar to antibodies concerning their binding affinities; however they possess 
unique features, which turn them into potential alternatives to the antibodies. Firstly, the aptamers 
are generated using in vitro settings contrarily to the antibodies that are generated in vivo 
(Jayasena, 1999; J. H. Lee, Yigit, Mazumdar, & Lu, 2010). In vitro selection allows oligomers to be 
screened against molecules that have weak immunogenicity or high toxicity (Jayasena, 1999; J. H. 
Lee et al., 2010; Tombelli, Minunni, Luzi, & Mascini, 2005). In addition, non-physiological and/or 
harsh conditions can be applied while selecting aptamers (Jayasena, 1999; J. H. Lee et al., 2010; 
Tombelli et al., 2005). For instance, the thermal denaturation of nucleic acids is reversible, as 
exhibited in polymerase chain reaction (PCR), whereas antibodies or proteins such as interleukin-1 
receptor (IL-1) are permanently denatured at temperatures higher than 53.5 °C (Remmele et al., 
2005). Secondly, since the method for the synthesis and purification of oligonucleotides is well 
developed, the batch-to-batch difference of aptamer products is minimal compared with that of 
antibodies (Jayasena, 1999; J. H. Lee et al., 2010; Tombelli et al., 2005). Also, the aptamers can 
be chemically modified with a variety of functional groups and/or fluorophores without loss of 
binding functionality (J. H. Lee et al., 2007). Besides, as mentioned above, aptamers are 
structurally versatile because they have basic stem-loop arrangements that form proper three-
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dimensional structures. These structures facilitate the formation of a complex with the target 
molecule. Thus, aptamers have high affinities to their targets, with dissociation constants at the low 
picomolar level, comparable to or better than antibodies (Gopinath, Awazu, & Fujimaki, 2012). 
Furthermore, aptamer-based ligands may exhibit prominent advantages that include site-
specific labeling, structure-controlled design and sequence-dependent amplification, which makes 
them an ideal molecular recognition tool for the development of biosensors (Zhang, Huang, Jiang, 
Shen, & Yu, 2007). In this context, besides the proliferated uses of aptamers instead of antibodies 
in established immunoassay techniques, the development of aptamer sensors with unique response 
strategies for homogeneous assays has been a subject of intensive research (Cho, Lee, & Ellington, 
2009).  
In addition, aptamers can be easily labeled for their use in diagnostics (Ulrich & Wrenger, 
2009). As the use of aptamers has been extended from basic biology of cellular processes and gene 
regulation to therapeutic and diagnostic applications, many patented aptamers are currently being 
tested in clinical trials and have been recently reviewed (Kanwar et al., 2011). One of the major 
challenges in this field is the development of general methods to convert the highly specific 
molecular recognition between aptamers and their targets into detectable signals. Conjugation of 
aptamers with labels, nanoparticles, enzymes, among others, can be an ideal way to overcome this 
hurdle (Y. S. Kim, Lee, & Gu, 2008).   
Systematic Evolution of Ligands by Exponential enrichment (SELEX) methodology is a 
combinatorial chemical procedure, commonly known as “in vitro selection” that allows the 
identification of nucleic acid sequences with unique properties from a random pool of sequences 
(an aptamer library), which were described above as aptamers (Figure 2). 
 
 
 
 
 
 
 
 
 
 
Figure 2 Isolation of aptamers using the SELEX procedure. Taken from Gopinath & Fujimaki, 2012  
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Since then, the SELEX methodology has been used to identify aptamers with high-affinity and 
specificity against hundreds of targets, becoming an important research tool especially in the 
discovery of new drugs and disease targets, clinical diagnosis, therapy and in food inspection. There 
have been attempts to search for aptamers that are specific to targets involved in various diseases, 
such as cancer and viral infection (K. M. Song et al., 2012). Developed aptamers have been 
studied primarily for applications as diagnostic or therapeutic tools. In 2004, the Food and Drug 
Administration (FDA) approved the first RNA aptamer (Macugen, Pegaptanib) for human use in age-
related macular degeneration treatment (AMD) targeting the vascular endothelial growth factor 
(VEGF) (Bunka & Stockley, 2006; Djordjevic, 2007; K.-T. Guo, Paul, Schichor, Ziemer, & Wendel, 
2008). SELEX was used in many of these cases to identify dsDNA sequences that are the strongest 
(consensus) binders to the protein of interest (Djordjevic, 2007). 
The choice between DNA or RNA aptamers depends essentially on practical considerations, 
and in part on the final application envisaged. In terms of a wide conformational diversity, RNA 
aptamers are naturally more flexible than the DNA molecules, but the RNA is more susceptible to 
degradation by nucleases which restricts their use in the presence of biological fluids. In terms of 
stability, using chemical modifications of the nucleotides, DNA aptamers are considered naturally 
more robust and display high levels of stability for biological applications than RNA aptamers. 
(Kulbachinskiy, 2007). Several strategies have been proposed to overcome the issue of RNA 
aptamers degradation, including their modification with 2′-aminopyrimidine, 2′-fluoropyrimidine or 
2′-O-methyl nucleotides to increase their stability (Burmeister et al., 2005; Chiu & Huang, 2009; 
Feng et al., 2008; Keefe & Cload, 2008; Mayer, 2009; Stoltenburg, Reinemann, & Strehlitz, 2007).  
Virtually, aptamers can be raised against any target. This feature makes them interesting 
molecules to recognize for example proteins that have been previously identified as biomarkers. One 
of the most well-known examples of in vitro selection of DNA oligonucleotides for targeting a specific 
protein is the thrombin-binding aptamer (TBA). This thrombin aptamer has been extensively studied 
and characterized, thus enabling the monitoring of thrombin levels in plasma or blood (Diculescu, 
Chiorcea-Paquim, Eritja, & Oliveira-Brett, 2010) It has been shown that in the presence of alkali 
metals, TBA forms an antiparallel quadruplex consisting of two G-quartets connected by two TT 
loops and one TGT loop. (Bock, 1992). In particular, the thrombin binding aptamer 1 (TBA1) and 2 
(TBA2) consist of two G-quartet conformations that selectively bind to specific and different epitopes 
of human -thrombin (Tasset, Kubik, & Steiner, 1997 ) (Figure 3). TBA1 is a 15-mer DNA aptamer 
which binds exosite I of thrombin (Fibrinogen Binding Site), with a dissociation constant (Kd) of 
approximately 26 nM (Bock, 1992; Paborsky et al., 1993; Tasset et al., 1997 ). TBA2 is a 29-mer 
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DNA aptamer binding to exosite II of thrombin (Heparin Binding Domain) with subnanomolar affinity 
(Sosic et al., 2011). This distinct recognition pattern allows their use in tandem, since a ternary 
complex could possibly be formed by simultaneous recognition of thrombin with different formats 
and detection methods have been demonstrated by few groups (Bang, Cho, & Kim, 2005; D. W. 
Huang, Niu, Qin, Ruan, & Zeng, 2010; A.-E. Radi, Sánchez, Baldrich, & O`Sullivan, 2005; Zhao et 
al., 2011)  
 
 
 
 
 
 
 
 
 
 
 
 
Some studies have reported the use of TBA to detect thrombin as summarized in Table 2. 
In most cases, it appears that the methodology adopted has been strongly influenced by the 
authors’ background, usually taking advantage of ELISA or nucleic acid-related protocols, as 
described below in Table 2. Discrepancies in values may also arise from the fact that each aptamer 
has a unique structure for target binding (E. Baldrich, Restrepo, & O'Sullivan, 2004). 
  
Figure 3 Schematic representation of the G-quartet of (a) TBA1 and (b) TBA2 (by 
Mfold web server) 
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Table 2 Assays reported from different authors in which TBA has been used. Adapted from Baldrich, E. et al., 
2004 and Centi, S. et al., 2007  
TBA 
Labelling and 
immobilization 
methods 
Assay Format Detection 
Limit of 
detection 
(LOD) 
Dissociation 
Constant (Kd) 
Reference 
In solution 
15-mer and 29-mer 
Magnetic 
Beads coated 
with 
StreptAvidin 
Electrochemical 0.45 nM 
15-mer: 26nM 
and 29-mer: 0.5 
nM 
(Centi, Tombelli, 
Minunni, & Mascini, 
2007) 
In solution 
Direct 
polymeric 
staining 
Change in color 
due to TBA folding 
10pM  (Ho & Leclerc, 2004) 
In solution (5`-
fluorphore 3`-
quencher)(2 
fluorophore) 
 
 
Molecular 
beacon 
Change in 
fluorescence 
373 pM 
429pM 
5.2±0.49nM 
(J. J. Li, Fang, & Tan, 
2002) 
In solution (5`-
fluorphore 3`-
quencher) 
Molecular 
beacon 
Change in 
fluorescence 
 10nM 
(Hamaguchi, Ellington, & 
Stanton, 2001) 
5`-NH-C6 on silica 
beads optic fibers 
(microarray) 
Competitive 
reusable 
Change in 
fluorescence 
(FITC-thrombin) 
1nM 300nM (M. Lee & Walt, 2000) 
3`-C7 glass slide 
immobilized, 5`-FITC 
Molecular 
beacon 
reusable 
Evanescent wave-
induced 
fluorescence 
anisotropy 
5nM 47nM 
(Potyrailo RA, Conrad 
RC, Ellington AD, & GM., 
1998) 
   
An OPN-directed RNA aptamer, OPN-R3, was recently isolated through SELEX technology. 
Binding studies with human OPN, were conducted using the OPN-R3 aptamer (Kd value of 18 ± 0,2 
nmol/l) and an unspecific competitor RNA aptamer. It was found that human OPN binds to OPN-
R3 in a specific manner (Zhiyong Mi et al., 2009). Besides, further research indicated that RNA 
aptamer binding to OPN blocks its interaction with cancer cell surface receptors to significantly 
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inhibit adhesion, migration and invasion in vitro, thus inhibiting local progression and distant 
metastases (Mi, Guo, & Kuo, 2009). 
 
1.1.2. Transducer 
Regarding the physical transducer, it is the part of the device that converts the recognition 
signal events into electrical (often digital) signals – biosensors can be categorized in various types, 
including resonant, photometric, thermal detection, ion-sensitive field-effect transistors (ISFETs), and 
electrochemical sensors (Tothill, 2009; Y. Zhou, Chiu, & Liang, 2012). Table 3 summarizes the 
sensing mechanism of each type of biosensor. 
 
Table 3 Types and sensing mechanisms involved in different biosensor. Adapted from: Tothill, 2009 and 
Zhou, Y. et al., 2012  
Type Sensing mechanism Transducer Measured property 
Resonant The change of the viscosity, mass leads to change 
of resonant frequency of the acoustic wave 
Mass sensitive Resonant frequency 
Thermal detection Bio-reaction results in exothermic character Thermal Heat of reaction or 
adsorption 
Photomeric The change of refractive of the solution leads to the 
change of refractive angle of the incident light 
Optical Surface Plasmon resonance 
angle, Fluorescence 
ISFETs The ionic analyte diffuses into the membrane 
hence change the potential difference at the 
detecting interface 
Ion-selective 
membrane 
Surface potential 
Electrochemical Bio-reaction results in ions production or 
consumption will create the charge transfer across 
the double layer of the transducer 
Electrochemical Potentiometric 
Amperometric 
Impedimetric 
 
1.1.2.1. Techniques for modification of surfaces: Self-assembled monolayers (SAM) and 
Layer-by layer (LBL)  
Self-assembled monolayers (SAM) and Layer-by-Layer (LBL) are methodologies that lead to the 
deposition of organic compounds on the biosensor surfaces. Among the commonly used substrates, 
gold presents some benefits for many electrochemical measurements. The gold surface can be 
functionalized and the type of chemistry selected is dependent on the type of terminal functional 
group linked to the aptamer (amine, thiol or biotin termini) (Velasco-Garcia & Missailidis, 2009). In 
addition, gold surfaces can be functionalized with SAM or LBL. 
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SAM provides molecular level control over the density and position of assembled molecules. 
SAM is capable of packing different types of molecules in an orderly fashion at the molecular level, 
which generates a multifunctional surface for multitasks. This layer of biological/chemical 
molecules is advantageous due to its simplicity of preparation, high sensitivity, and few limitations 
in the detection range of an analyte, and most importantly, the versatility of the modification that no 
other organic materials could match (Y. Zhou et al., 2012). As a substrate for monolayers 
assembly, gold presents interesting features: it is air-stable and commercially available from several 
sources as films and particles; it binds thiols with a high affinity (Balamurugan, Obubuafo, Soper, & 
Spivak, 2008), and the films are stable in complex liquid media containing target biomolecules. The 
monolayer can be designed to prevent non-specific adsorption of aptamers to the gold surface and 
it plays an important role in applications that require long-term storage stability (Kuralay, 
Campuzano, & Wang, 2012). 
On the other hand, the layer-by-layer (LBL) approach is a convenient technique for the 
bottom-up assembly of multi-layered polymer films, because it allows the deposition of oppositely 
charged polyelectrolytes onto solid substrates (Du et al., 2010). The nature of the assembly process 
leads to precise, nanoscale control of film thickness and composition through the appropriate 
choice of the components, the number of layers, and the order of their deposition (Sultan, Walsh, 
Monreal, & DeRosa, 2009; J. Wang, 2006; S. Xie & Walton, 2010). This method is highly versatile 
since several polyelectrolytes can be chosen. Biological macromolecules such as 
polypeptides/proteins, polysaccharides, nucleic acids and even viruses can serve as building blocks 
for these multilayer films. Sultan et al. (2009) reported that when embedded in or attached to LBL 
polyelectrolyte matrix, aptamers could maintain their affinity and specificity for the cognate target. 
The LBL technique has been reported for protein detection using self-assembled multilayers with 
ferrocene-appended poly(ethyleneimine) (Fc-PEI), carbon nanotubes (CNTs), and aptamers (Du et 
al., 2010). 
Compared with SAM, these LBL multi-layers with three dimensional structure can bring in, 
not only more probes to produce an amplified signal, but also more molecular recognition elements 
to improve the sensitivity of the detection, making the stable membrane property of the multi-layer 
widely used in biosensors (Du et al., 2010). 
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1.2. Electrochemical detection 
Electrochemical transducers are the most widely used in platforms for patient diagnosis 
since they are portable, simple, easy to use, low cost, minimal simple-to-operate, robust power 
requirements and independence of sample turbidity and in most cases disposable (A.-E. Radi, 
2011; F. Wei, Lillehoj, & Ho, 2010). The electrochemical instruments used with the biosensors have 
been miniaturized to small pocket size devices which make them applicable for “alternative-site” 
testing, emergency-room screening, bedside monitoring or home self-testing (Tothill, 2009; J. Wang, 
2006).  
The name electrochemical biosensor is applied to a molecular sensing device which 
intimately couples a biological recognition element to an electrode transducer, in which the purpose 
of the transducer is to convert the phenomenon into a suitable and readable electrical signal. 
Potentiometric and amperometric biosensors are the two most common types of 
electrochemical biosensors. Potentiometric biosensors use ion-selective electrodes to detect an 
electrical response in the molecular recognition element (Han, Liang, & Zhou, 2010). A true 
potentiometric aptasensor has been recently reported. This device was based on 
poly(phenothiazine) conducting polymers electropolymerized on a glassy carbon electrode. Avidin-
modified polymer surfaces obtained by direct electrostatic precipitation have then been used to 
immobilize biotinylated anti-thrombin DNA aptamers. Measurement of the difference in the potential 
of the sensor enabled the potentiometric thrombin detection in a concentration ranging from 10-9 to 
10-6 M (Evtugyn, Porfireva, Hianik, Cheburova, & Budnikov, 2008). 
Amperometric transducers measure the current that is produced when a potential is 
generated between two electrodes. Oxidation or reduction reactions produce a current, which can 
then be measured (J. Wang, 2006). Amperometric-based biosensors for cancer detection, using 
sequence-specific DNA as the recognition element, have an enormous potential in the diagnosis 
field (Ikebukuro, Kiyohara, & Sode, 2005). Other examples include the work by Ikebukuro and co-
workers (2004) that developed the first electrochemical aptasensor with an amperometric sandwich-
based biosensor based on glucose dehydrogenase-labeled signaling aptamers. The GlucoWatch™ is 
a glucose sensor that was developed to enable non-invasive, continuous measurement of blood 
glucose levels in diabetic patients. This device works like a wristwatch and takes blood glucose 
readings through the skin via reverse ion-transfer, a process whereby a small electrical signal brings 
glucose to the skin surface so that it can be measured.  
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Electrochemical aptasensors have been recently developed for multiplexed protein 
measurements. In fact, since most cancer diseases are associated with the presence of more than 
one tumor marker, developing an effective aptasensor for simultaneous measurement of co-existing 
tumor markers may be valuable to improve the detection accuracy and to deliver more precise 
information on diagnosis, prognosis and treatment (Zhao(a) et al., 2012). 
Electrochemical sensors are part of an electrochemical cell that often consists of three 
electrodes. A distinctive three electrode electrochemical cell consists of a working (or indicator) 
electrode of a chemically stable solid, conductive material, such as gold; a reference electrode and 
an auxiliary electrode (Ronkainen, Halsall, & Heineman, 2010) as shown in Figure 4. The working 
electrode serves as the transduction 
element in the biochemical reaction, 
while the counter electrode establishes 
the connection with the electrolytic 
solution so that a current can be applied 
to the working electrode (Grieshaber, 
MacKenzie, Voros, & Reimhult, 2008; 
Beate Strehlitz et al., 2008). Electroactive 
reporters such as methylene blue (MB), 
ferrocene, ferrocene-bearing polymers, 
ruthenium complexes and [Fe(CN)6]4−/3− are 
commonly used for signal transduction in 
electrochemical aptamer-based sensors. These reporters can be covalently conjugated to the 
aptamer itself, conjugated to a complementary oligonucleotide or indirectly linked to aptamers (Cho 
et al., 2009). Screen- printed electrodes (SPEs) have been used in several electrochemical DNA 
sensors due to their straightforward fabrication, high uniformity and material versatility (F. Wei et al., 
2010). Therefore, SPEs can offer an inexpensive solution with the additional advantage of flexibility 
in the biosensor shapes (D. Wei, Bailey, Andrew, & Ryhanen, 2009). Screen-printed technology has 
been reported as an attractive method for mass production of sensors (Alonso-Lomillo, Dominguez-
Renedo, Matos, & Arcos-Martinez, 2009; Tothill, 2009). 
 
 
Figure 4 Screen-printed electrode with its diagram. Ref., 
reference electrode; Aux., auxiliary electrode; and Work, 
working electrode. Adapted from Ronkainen et al., 2008 
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1.2.1. Voltammetry  
Voltammetry provides an electroanalytical method for gathering information on one or more 
analytes by measuring the current as a function of the potential in electrochemical aptasensors. 
Several types of experiments may be performed to collect information from voltammetry including 
cyclic voltammetry, square-wave voltammetry, and stripping voltammetry to name a few common 
techniques (Feng et al., 2008; Ikebukuro et al., 2005; K. M. Song et al., 2012; Beate Strehlitz et al., 
2008; F. Wei et al., 2010; D. Xu et al., 2005). 
Since there are many ways to vary a potential, there will also exist many forms of 
voltammetry, including polarography (DC Voltage), linear sweep, differential staircase, normal pulse, 
reverse pulse, differential pulse, among others. However, cyclic voltammetry is one of the most 
generally used forms and it is useful to obtain information about the redox potential and 
electrochemical reaction rates (e.g. the chemical rate constant) of analyte solutions. 
The voltage is measured between the reference and the working electrodes, while the current is 
measured between the working and the counter electrode. The measurements are plotted as 
current versus voltage, also known as a voltammogram. The shape of the voltammogram for a 
specific target depends not only on the scan rate and the electrode surface, which is different after 
each adsorption step, but can also depend on the catalyst concentration (Grieshaber et al., 2008). 
Moreover, the detection can be either “signal on” or “signal off”, depending on how the redox 
reporter is shielded from the electrode, resulting in maximum or minimum peaks, respectively on 
the voltammograms (Cho et al., 2009; Shiping Song, Wang, Li, Fan, & Zhao, 2008). 
Additionally, through voltammetry it is possible to infer about some important parameters such 
as the biosensor affinity and probe-target binding; selectivity (especially important in real-world 
samples where the target concentration can be much less than the concentration of non-target 
biomolecules present); limits of detection and reproducibility (the detection limit can be determined 
by measuring the sensor response to a dilution series and determining the target smallest 
concentration at which the sensor response is clearly distinguishable from the response to a blank 
solution.); dynamic range (ratio between the largest measurable target concentration and the limit 
of detection); amplification (amplification techniques lay outside the domain of label-free impedance 
biosensors); and multiplexing (it means detecting several targets in the same biological sample is 
possible if different surface regions are functionalized with different probes) (Daniels & Pourmanda, 
2007). 
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1.3. Immobilization methods 
The critical step in the development of electrochemical aptasensors is the immobilization of the 
aptamers (biological recognition element) to the electrode surface. It is crucial to develop strategies 
for the reliable immobilization of aptamers so that they retain their biophysical characteristics and 
binding abilities, as well as for minimizing non-specific binding/adsorption events. In theory, these 
strategies are similar to those applied hitherto for the immobilization of single- or double-stranded 
DNA in DNA biosensors for the detection of DNA damage. As mentioned, the control of this step is 
essential to ensure high reactivity, orientation, accessibility, and stability of the surface-confined 
probe and to avoid non-specific binding (A.-E. Radi, 2011; Audrey  Sassolas, Leca-Bouvier, & Blum, 
2008). 
Centi et al. (2007) stated that “The procedure to fix the aptamer to the surface is of paramount 
importance to obtain an ordered and oriented layer able to ensure, as much as possible, the 
flexibility of the bioreceptor without altering the affinity for the target molecule and selectivity that the 
aptamers show in solution”(Balamurugan et al., 2008). If immobilization is declined, it could lead 
to partial or complete loss of the target activity, due to possible structure deformation. Thus, to 
avoid this issue, proteins should be attached onto surfaces without affecting conformation and 
function (Rusmini, Zhong, & Feijen, 2007). 
When developing an aptamer diagnostic device there are several different approaches for the 
immobilization of aptamers, which depend upon the chemical composition of the surface, the 
availability of suitable aptamer linkers, and the chemistries used for attachment (Balamurugan et 
al., 2008). Several substrates can be used as supports for the aptamer immobilization such as 
gold, silicates, carbon nanotubes (Fabre, Samorì, & Bianco, 2012; K. Guo et al., 2011) and 
polymers (L. Zhou, Wang, Wang, & Ye, 2011). 
When developing an aptasensor, it is of utmost importance to define adequate immobilization 
strategies in order to maximize the performance of the aptamer-based analytical device 
(Balamurugan et al., 2008). Thus, in order to immobilize the aptamer onto the solid support it is 
required that either the 5′ or 3′ -end of the aptamer is modified (Gopinath et al., 2012). Although 
both positions can be used for the aptasensor development, there are very few studies looking at 
the effect of the two types of end attachment. Recent work suggests that it depends on the 
particular aptamer (Cho, Collett, Szafranska, & Ellington, 2006), although for biological targeting it 
may be that the 3’ end is more suitable, since the 3’ end is the primary target for exonucleases, 
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and thus its coupling to the solid support would simultaneously confer resistance to nucleases 
attack (Velasco-Garcia & Missailidis, 2009). 
Few immobilization techniques for fixing aptamers onto biosensor surfaces have been 
developed in the past years, which are mainly based on the following three mechanisms: physical 
(adsorption), covalent (chemisorption with thiol and covalent attachment to chemically-modified 
surfaces by chemical groups such as hydroxyl, carboxyl and amino), and bio-affinity immobilization 
(using for example the Avidin-biotin interaction method) (Rusmini et al., 2007; Audrey  Sassolas et 
al., 2008; L. Zhou et al., 2011) . 
The choice of the best immobilization strategy is still an open question, although it is 
unlikely that one structure will be optimal for all proteins. Consequently, the extrapolation of 
immobilization strategies from one system to another for different classes of proteins is difficult and 
mostly unsuccessful due to the wide subset of characteristics and functional properties of proteins. 
Therefore, several unsolved challenges are involved in the immobilization of the aptamers (Rusmini 
et al., 2007). 
 
1.4. Immobilization techniques 
1.4.1. Physical adsorption 
Physical adsorption is an immobilization method that does not requires any nucleic acid 
modification. It consists in placing the aptamer solution in contact with the surface for a well-
defined period of time, and subsequently washing off any non-adsorbed biomolecules. It is based 
on the ionic, hydrophobic and Van der Waal’s forces that take part in the interaction and will 
depend on the particular protein and surface involved. The resulting layer is likely to be 
heterogeneous and randomly oriented, since each molecule can form many contacts in different 
orientations for minimizing repulsive interactions with the substrate and previously adsorbed 
proteins (Rusmini et al., 2007), however, by its weakness, reversible binding could usually occur (A. 
Sassolas, Blum, & Leca-Bouvier, 2011). 
Ocana et al. (2012) developed a reusable impedimetric aptasensor for the detection of 
thrombin in which the immobilization of the aptamer onto the transducer surface was conducted by 
a wet physical adsorption procedure.  
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1.4.2. Covalent immobilization 
DNA immobilization by covalent attachment is often used (Audrey  Sassolas et al., 2008) and 
preferred over adsorption (A. Sassolas et al., 2011). Thiol-metal interactions are frequently used to 
bind biomolecules covalently onto gold surfaces (Bai et al., 2008; Y. S. Kim et al., 2008). Noble 
metal surfaces display strong affinity to thiol groups and consequently enable the formation of 
covalent bonds between the sulfur and gold atoms (A. Sassolas et al., 2011).  
The three most common groups used for surface covalent attachment to chemically-modified 
sensor surfaces are hydroxyl, amine, and carboxylic acid functional groups. The choice of this kind 
of surface functionalization depends on the types of terminal functional groups linked to aptamers 
that are available (Balamurugan et al., 2008). These groups interact with chemical groups (such as 
amino) through covalent binding, leading to a layer of ordered film on the sensor surface (Audrey  
Sassolas et al., 2008; L. Zhou et al., 2011). 
 
1.4.3. Biocoatings/Bioaffinity 
Chemical affinity reactions allow a gentle oriented immobilization of proteins, providing an 
important improvement over other immobilization techniques (Rusmini et al., 2007). 
Avidin is a glycoprotein which contains four identical subunits with a combined mass of 67 
to 68 kDa (Orita, Tomita, Harada, & Kato, 2012). The specific and strong interaction between avidin 
(or one of its derivatives like streptavidin) and biotin has been widely explored for surface 
immobilization of a number of bio-receptors, including aptamers (Balamurugan et al., 2008), and it 
has been used in several recent studies (L. J. Chen et al., 2011; General, Dragomirova, & 
Meirovitch, 2011).  
Biotin- avidin interaction is one of the ideal methods for aptamer fixation on a variety of sensor 
surfaces, as its interaction exhibits the highest known affinity in nature (Kd =1015 M-1), robustness 
and simplicity (Balamurugan et al., 2008; Orita et al., 2012; A. Sassolas et al., 2011). Specifically, 
compared with other fixation methods, each avidin molecule can bind with four biotinylated 
aptamers as shown in Figure 5. This increases the amount of aptamers potentially bound to the 
sensor surface, reduces the incidence of non-specific adsorption, and improves sensor signal-to-
noise ratio (Zhou et al., 2011).  
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Avidin-biotin method was used by Minunni and collaborators (2004) to activate a gold film-
coated quartz chip using 11-mercaptoundecanol and carboxylated dextran to interact with avidin 
using 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide sulfosuccinimide (EDC/NHS). Afterwards, 
the biotin-labeled aptamers were attached to the avidin-modified quartz chip. The sensor can be 
used to detect HIV-1 transactivator protein, being the linear detection range between 0–2.5 mg L–1, 
and the detection limit around 0.65 mg L–1 (Minunni, Tombelli, Gullotto, Luzi, & Mascini, 2004). In 
Hianik et al., (2007) it was used the avidin-biotin method for aptamer immobilization, in which 
quartz crystal microbalance (QCM) was the method used for mass detection to study the interaction 
of thrombin with DNA aptamers exhibiting two different configurations. The authors suggested that 
immobilization of the aptamer by means of avidin-biotin methodology provides the best results in 
sensitivity comparing to other immobilization methods using dendrimers or immobilization via 
chemisorption of the aptamer onto a gold surface (Hianik, Ostatna, Sonlajtnerova, & Grman, 2007).  
The avidin–biotin conjugation methods possess several advantages, for example they do not 
depend on the isoelectric point of the protein. Nevertheless, the use of avidin/biotin immunoassays 
is currently limited because of their sensitivity to high temperature and organic solvents (Orita et al., 
2012).  
  
Figure 5 Illustration of Avidin-biotin interaction. Each Avidin molecule can bind four biotinylated 
aptamers. Taken from http://www.piercenet.com/media/Avidin-Biotin-Interaction1.jpg 
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1.5. Design Strategies for Aptasensors 
A sensitive and simple method to use aptamers as recognition elements for the 
development of biosensors (aptasensors) is to transduce to an electrochemical signal the real-time 
biological phenomena in solution, or through aptamer immobilization onto a solid support (Hong et 
al., 2012; Minunni et al., 2004; O'Sullivan, 2002). As sensing probes, aptamers are extremely 
advantageous in a biosensor. In fact, they can be modified for immobilization purposes and can 
incorporate particular reporters, without influencing their affinity, which has been very helpful for a 
number of design methods (Balamurugan et al., 2008; Phillips et al., 2009). Regarding the design 
strategies for most of the electrochemical aptasensors, four broad classes can be defined 
depending on the assay format and the method of detection: (a) sandwich mode; (b) label-free 
aptamer sensor-using electrochemical impedance spectroscopy (EIS); (c) aptamer conformational 
changes; and (d) target-induced displacement mode (TID), as illustrated in Figure 6 (Abe, Yoshida, 
& Ikebukuro, 2013; Han et al., 2010; Y. Huang et al., 2012; A.-E. Radi, 2011; Audrey Sassolas, 
Blum, & Leca-Bouvier, 2009; Y. Xu, Cheng, He, & Fang, 2009). 
 
Figure 6 The schematic representation of protein strategies for electrochemical biosensors: (a) Sandwich assay using aptamers 
combining various signal amplification methods: enzyme, nanoparticle and carbon nanotubes means of measuring the 
concentration of bound target via impedance spectroscopy; (b) Impedimetric aptasensor: the binding of a target to the aptamer 
reduces the electron transfer (et) of a small redox mediator diffusing to the electrode surface and the increase the interfacial 
resistance, which provides a means of measuring the concentration of bound target via impedance spectroscopy; (c) Aptamer 
Conformational Changes: in the absence of target, the aptamer is largely unfolded, allowing for frequent collisions between the 
terminal redox moiety and the electrode. After target binding, the aptamer folds, enhancing electron transfer and producing a 
signal-on aptasensor; (d) Displacement Assays: target molecules in a sample displace labeled-target molecules previously 
bound to the sensor surface. Adapted from: Radi et al., 2011 and Abe, K., Yoshida, W., & Ikebukuro, K., 2013 
                     Introduction 
21 
 
1.5.1. Sandwich Assay (SA) 
The sandwich structure strategy presents several advantages as compared to the strategy 
that uses only one recognition element to capture and label the target biomolecules. These 
advantages include its high sensitivity and simple operation in what regards the biosensor 
fabrication for biosensor fabrication. In a sandwich structured biosensor, the sequence is firstly 
immobilized on the electrode to hybridize with a certain part of the target DNA, and then the 
probing sequence is available to react with another part of the target sequence. The electroactive 
label at the probing sequence thus electrochemically transduces the presence/binding of the target 
sequence. 
Therefore, as a strategy employed for aptasensor in sandwich manner, the target should 
have two or more recognition elements, namely the one that binds to the aptamer, used as 
capturing element to be immobilized on the electrode surface and catch target molecules; and the 
other one that serves as a probing element to mark the target with electroactive molecules or 
nanoparticles (Y. Xu et al., 2009).  
To construct highly sensitive detection systems, some researchers have attempted the 
conjugation of nanoparticles (NPs), enzymes, quantum-dots (QDs) and carbon nanotubes (CNT) 
with aptamers (Abe et al., 2013).  
 
1.5.2. Label-Free Aptamer Sensor -Using Electrochemical Impedance Spectroscopy (EIS) 
 Electrochemical impedance spectroscopy (EIS) has been mainly applied to study corrosion 
systems, specifically to monitor the resistance components of the impedance response (Grieshaber 
et al., 2008; Y. Xu et al., 2009). Therefore, it reflects changes in a diffusion-limited electrochemical 
process, presumably due to steric hindrance created by the bound molecules to the immobilized 
aptamer and repulsion between electron mediators and immobilized molecules (Abe et al., 2013). 
 
1.5.3. Aptamer Conformational Changes 
 In this detection strategy, the DNA ligands recognize their targets primarily by their special 
shape and not by their sequence. They are capable to fold into unique complex intramolecular 
secondary and tertiary structures, binding and crosslinking the target molecule in a large surface 
area. Therefore, they are able to distinguish a small structural change in the target molecules. 
Besides, aptamers change its conformation through Watson-Crick base pairing and drastically, in 
some cases, they reduce the electronic transfer distance of the electroactive probing group from the 
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aptamer sequence end to the electrode surface, or desorb the electroactive intercalators from the 
aptamer bases, consequently resulting in a change in the electrochemical current (Abe et al., 
2013). This approach based on the shift of the aptamer structure has the advantage of a readily 
regeneration by varying temperature or ionic strength (Y. Xu et al., 2009). 
The changes of electrochemical features after target binding can be correlated to the target 
concentration. Signal-on (positive readout signal) and less sensitive signal-off (negative readout 
signal) aptasensors have been described, based on electrochemical signal producing design and 
signal amplifications methods, namely target binding-induced conformational change of aptamers, 
or on target binding-induced strand displacement, 
or even on both processes (Audrey Sassolas et al., 
2009). “Signal-on” and “signal-off” biosensor 
functioning are described in Figure 7.   
The “signal-off” sensor strategy corresponds 
to the situations in which target recognition is 
signaled by the loss of an initially high current. An 
inconvenient of such functioning is that it limits 
the signal gain: one can never suppress more 
than 100% of the original current. Conversely, 
“signal-on” sensors, in theory, can provide an 
enormous signal gain as the background observed in the absence of target is pushed towards zero 
(Daniels & Pourmanda, 2007). 
 
1.5.4. Target-Induced Displacement Mode (TID) 
In the TID mode, the complementary sequences of aptamers, instead of the aptamers 
themselves, are used as anchors to localize the aptamers. After incubation with targets, the formed 
target-aptamer complexes will be released into the solution, which leads to changes of detectable 
signals (Han et al., 2010).  
 
1.5.5. Other electrochemical strategies 
 A direct labeling method has also been used to monitor the presence of target proteins on 
the electrode surface. Labels such as enzymes, metal nanoparticles (NPs), other redox species 
Figure 7 Signal-off (A) and signal-on (B) approaches 
using an aptamer labeled with a redox active 
molecule. Taken from de-los-Santos-Álvarez et al., 
2008 
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such as methylene blue (MB), ferrocene (Fc), potassium ferrocianate (K3Fe(CN)6) or anthraquinone 
have been used (Audrey Sassolas et al., 2009; K. M. Song et al., 2012; Beate Strehlitz et al., 
2008). Frequently, the amount of the labeled molecules indicates the amount of DNA targets in the 
sample, either in a direct detecting or a competitive detecting mode (F. Wei et al., 2010). These 
labels are commonly covalently linked to the terminal groups of aptamers.  
The labeled position has to be carefully selected so it does not interfere with the folding of 
the aptamer, or to guarantee that it does not modify an essential binding group. If labeling is 
incorrectly performed it can drastically change the anticipated binding properties, and the yield of 
the target-label coupling reaction will be extremely variable. Therefore, an indirect labeling scheme 
often referred to as a sandwich assay is commonly used for protein detection. This requires two 
probes that bind to different regions of the target, yielding enhanced selectivity but increasing 
development costs and limiting its use in research settings (Daniels & Pourmanda, 2007). 
Table 4 presents a comparison between the properties of several electrochemical 
aptasensors against thrombin. 
  
Table 4 The comparison of the representative electrochemical aptasensor using different detection schemes. 
Adapted from: Hamula et al., 2006; Kim et al., 2008; Sassolas et al., 2009; Xu et al., 2009; Radi, 2011 and 
Abe, 2013 
Aptasensing Strategy Material Detection Limit Reference 
Sandwich 
structure 
Marking enzymes on probing 
recognition element 
 
GDH 10 nM 
(thrombin) 
(Ikebukuro et al., 2005) 
Nanoparticles on probing 
recognition element 
 
Au NPs 0.1ng/mL (He, Shen, Cao, & Li, 
2007) 
Magnetic beads coated with 
streptavidin 
 
StreptAvidin magnetic 
beads 
0.45 nM 
(thrombin) 
(Centi et al., 2007) 
Marking electroactive molecules/ 
nanoparticles on probing 
recognition element 
 
CdS particles 0.14 nM 
(thrombin) 
(Numnuam et al., 2008) 
Screen-printed carbon electrode first 
aptamer immobilization(SPCE) and 
Au NPs second aptamer 
immobilization 
Au NPs 1 nM 
(thrombin) 
Look up at (A.-E. Radi, 
2011) 
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Aptasensing Strategy Material Detection Limit Reference 
EIS Change at electrode Rct Interference of protein 
to [Fe(CN)6]3-/4- 
2 nM 
(thrombin) 
(A. E. Radi, Acero 
Sanchez, Baldrich, & 
O'Sullivan, 2005) 
Protein binding event via 
monitoring the interfacial 
electron transfer resistance with 
EIS 
Interference of protein 
to [Fe(CN)6]3-/4- 
0.1 nM 
(thrombin) 
(Cai, Lee, & Hsing, 
2006) 
Protein binding event via 
monitoring the interfacial 
electron transfer resistance with 
EIS 
Guanidine 
hydrochloride 
1.0x10-14 mol L-1 
(thrombin) 
(Y. Xu, Yang, Ye, He, & 
Fang, 2006) 
Physical and electrical properties 
of carbon thin film pyrolyzed 
with a positive photoresist 
Pyrolyzed 
carbon 
0.5nM- 500nM 
(thrombin) 
(J. A. Lee et al., 2007) 
Molecularly imprinted polymers Methylene green (MG) 0.5 nM 
(thrombin) 
(Evtugyn et al., 2008) 
Changes of the interfacial 
properties of the electrode 
Graphite-epoxy 
composite electrode 
(with [Fe(CN)6]3-/4- ) 
4.5nM 
 (thrombin) 
(Ocana, Pacios, & del 
Valle, 2012) 
Aptamer 
Conformational 
Changes 
Signal-Off Releasing intercalated 
MB 
11 nM 
(thrombin) 
(Bang et al., 2005) 
Signal-On MB labeling 6.4 nM 
(thrombin) 
(Xiao, Lubin, Heeger, & 
Plaxco, 2005) 
Chronoamperometric beacon 
system 
Fc-labeled 3.5nM 
(thrombin) 
(Mir, Vreeke, & Katakis, 
2006) 
Signal-On Pushing labeled 
Fc close to electrode 
0.5 nM 
(thrombin) 
(A. E. Radi, Acero 
Sanchez, Baldrich, & 
O'Sullivan, 2006) 
    
 Switching structures of aptamers 
from DNA/DNA duplex to 
DNA/target complex 
MB labeling 3 nM 
(thrombin) 
(Yan, Wang, & Chen, 
2011) 
Target Molecule 
Displacement 
Displacing probing protein 
from electrode 
Quantum dots tagged 
Probing proteins 
0.5 pM 
(thrombin) 
(Hansen et al., 2006) 
Displacing complementary 
sequence from electrode 
Fc-labeled 
complementary 
sequence 
<2 nM 
(thrombin) 
(Lu, Zhu, Yu, & Mao, 
2008) 
Displacing CdS-CDs with 
sequence from the electrode 
CdS nanoparticle 
surface-modified  B- 
cyclodextrins (CdS-
CDs) 
4.6x10-12 M 
(thrombin) 
(Fan, Li, Wang, He, & 
Fang, 2012) 
Displacing Fc-AuNPs from 
electrode 
Ferrocene-coated gold 
nanoparticles (Fc-
AuNPs) 
100 pM 
(alfa- thrombin) 
(Kwon, Jeong, & Chung, 
2011) 
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Aptasensing Strategy Material Detection Limit Reference 
Signal Amplification 
Using Sandwich 
Assay Format 
Amplification ability of Au 
nanoparticles carrying multiplex 
CdS NPs 
Au NPs with CdS NPs 5.5x10-16 M 
(thrombin) 
(Ding, Ge, & Lin, 2010) 
Other 
Electrochemical 
Aptasensor 
Direct labeling method MB labeling 10 nM 
(thrombin) 
(Hianik, Ostatna, 
Zajacova, Stoikova, & 
Evtugyn, 2005) 
EQCM Mass increase 0.3 nM 
(thrombin) 
in (Y. Xu et al., 2009) 
Potential change Potential change 
at aptamer electrode 
1 nM 
(thrombin) 
In (Y. Xu et al., 2009) 
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1.6. Biosensor parameter criteria 
Although the development of clinical sensors and biosensors has increased in recent years, 
improvements in sensitivity, selectivity, limits of detection, fast response and miniaturization are yet 
to be achieved. Health care appears to provide the best opportunity for sensor development.  
Electrochemical biosensors are the most common in the clinical field, due to their high 
sensitivity and selectivity, portability, rapid response time and low cost. 
The characterization of a biosensor response is important since the sensor operating 
parameters will dictate its performance and further optimizations  (Justino, Rocha-Santos, & Duarte, 
2010) (Thévenot, Toth, Durst, & Wilson, 2001). The fast spread of the biosensors field led to the 
actual situation in which performance criteria are still not well defined. Thus, standard IUPAC 
definitions will be followed, in order to establish the guidelines for reporting characteristics of a 
biosensor response (Thevenot, Toth, Durst, & Wilson, 1999). 
Several parameters should be discussed in order to fully characterize a biosensor such as 
calibration, sensitivity, limit of detection (LOD), selectivity, steady-state responses times and 
concepts concerning the final results, i.e., reproducibility, reliability, stability and lifetime for 
assessing analytical accuracy (Justino et al., 2010; Thevenot et al., 1999). 
Sensor calibration is the first point to evaluate. This calibration is performed using standard 
solutions of the analyte and plotting steady-state responses versus analyte concentrations. Steady-
state response time refers to the time necessary to reach 90% of the saturation (Thévenot et al., 
1999). Within the linear range of response for the method, the sensitivity is a well-defined value. If a 
small change in the analyte concentration causes a large change in the response it can be 
concluded that the analytical method is sensitive (Justino et al., 2010). Regarding the working 
concentration range, the LOD corresponds to the concentration at which the smallest signal can be 
detected with an acceptable degree of certainty for a given analytical procedure (Justino et al., 
2010). Additionally, the biosensor selectivity is expressed as the ratio of the signal output with the 
analyte alone to that with the interfering substance alone, both at the same concentration. 
Consequently, the response of the analyte of interest can be differentiated from other responses. 
Reproducibility is a measure of the discrepancy on a series of observations or results 
performed over a period of time. Usually, it is determined for the analyte concentrations within the 
usable range of the biosensor. Reliability is also crucial for the biosensor precision. It depends both 
on the selectivity and reproducibility of results. A biosensor is reliable when the response is directly 
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related to the analyte concentration and it does not vary with concentration fluctuations of 
interfering substances within the sample matrix (Justino et al., 2010; Thévenot et al., 2001). 
Depending on the sensor geometry, method of preparation, as well as on the receptor and 
transducer used, the working stability of a biosensor response will be altered. These parameters are 
intrinsically dependent upon the response rate-limiting factor, i.e. by the biological recognition 
reaction. Hence, to eliminate this type of variations, experimental conditions such as pH, ionic 
strength, temperature, analyte concentration, and presence of organic solvents, as well as sample 
size and sample pre-treatment have to be established a priori. Furthermore, to have a good storage 
stability there are a number of variables that must be considered including the dry/wet atmosphere 
composition, pH, buffer composition and presence of additives (Labuda et al., 2010; Thevenot et 
al., 1999). Finally, the characterization of the biosensor parameters is also essential for the 
assessment of the sensor lifetime. 
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2. Materials and methods 
2.1. Fluorescence anisotropy assays  
Fluorescence is a technique commonly used to measure binding events, and the fluorescence 
recognition reaction does not require the separation of the blank reagent (control) from the test 
media (Gokulrangan et al., 2005). With the recent advancements in synthesis of fluorochrome-
labeled oligonucleotides and the advent of more sophisticated fluorescent plate-readers, 
fluorescence offers an excellent methodology for determining binding affinities between different 
species. A significant anisotropy change will be observed when an aptamer labeled with a 
fluorescent dye (e.g. fluorescein) binds to the target molecule (e.g. protein). By placing the 
fluorescent signal on the smaller DNA molecule, binding to the much larger protein results in a 
substantial change in anisotropy, and therefore enables the determination of binding constants 
within the range of 10-10 to 10-3 M (Owen & McMurray, 2009) (Figure 8).  
Several label-based or label-free techniques have been demonstrated to achieve the reliable 
detection of proteins, including the enzyme-immunosorbent assay (ELISA). Combining real-time 
measurements with sensitivity, selectivity and reversibility it is interesting to monitor individual 
binding events (S. Liu et al., 2011). 
 
2.1.1. Materials and chemicals 
Thrombin-binding DNA sequences used in the current work were designated unmodified 15-
mer Thrombin binding aptamer 1 (TBA1): 5’-GGT TGG TGT GGT TGG-3’,  unmodified 26-mer 
Thrombin binding aptamer 2 (TBA2) : 5’-AGT CCG TGG TAG GGC AGG TTG GGG TGA CT-3’ and 
Osteopontin-binding RNA sequence (OPN-R3): 5’- 
Figure 8 Schematic of DNA aptamer binding to thrombin. Taken from: 
http://www.piercenet.com/method/Avidin-biotin-interaction) 
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CGGCCACAGAAUGAAAAACCUCAUCGAUGUUGCAUAGUUG-3’ (Table 5). In all aptamers, the 
fluorophore 6-carboxyfluorescein was attached to the 5`-end of the DNA and RNA (in the case of 
the OPN-R3) to enable their detection by the fluorescence anisotropy assay. All the aptamers 
(thrombin and osteopontin) were purchased from IDT Integrated DNA Technologies (Munich, 
Germany). The stocks were dissolved in deionized purified MilliQ water, pH 6, to a final 
concentration of 100 μM, and from this volume several aliquots were stored at −20°C.  
Table 5 List of the DNA and RNA sequences used in the experiments 
Designation Sequence 
Labeled unmodified 15-mer Thrombin 
binding aptamer 1 (TBA1) 
5`- 6FAM- GGTTGGTGTGGTTGG-3` 
Labeled unmodified 26-mer Thrombin 
binding aptamer 2 (TBA2) 
5`- 6FAM- AGTCCGTGGTAGGGCAGGTTGGGGTG-3` 
Labeled modified Osteopontin aptamer 
(FAMR3-OPN) 
5’-6FAM-CGGCCACAGAAUGAAAAACCUCAUCGAUGUUGCAUAGUUG-3’. 
 
 
Thrombin from human plasma (T6884) was purchased from Sigma-Aldrich (Saint Louis, 
MO, USA) and human osteopontin (hopn, catalog N. 1433-OP/CF) was purchased from R & D 
Systems (Minneapolis, MN 55413, USA). Other proteins such as Bovine serum albumin (BSA) and 
Bovine plasma osteopontin (bopn) were bought from Sigma Chemical Co. (St Louis, MO, USA) and 
from R & D Systems (Minneapolis, MN 55413, USA), respectively. All proteins were dissolved in 
deionized purified (MilliQ) water and proper aliquots were stored according to the supplier’s 
instructions.  
All other chemicals used in the current work were of analytical grade and used without 
further purification. Deionized water was obtained using an ultrapure water system Millipore (ELIX5. 
USA) and had an electrical resistance larger than 18.2 MV. 
 
2.1.2. Fluorescence apparatus 
The method used to evaluate the aptamers fluorescence was described by Li et al., 2007 
(W. Li, Wang, Tan, Ma, & Yang, 2007). Briefly, fluorescence measurements were performed in 96-
dark well plates using an ELISA (Synergy HT, BIO-TEK, IZASA) equipped with a thermostat holding a 
temperature control accuracy of 0.1˚C. All experiments were carried out at 25˚C. The fluorescence 
of the aptamers was monitored by exciting the sample (6-FAM-labeled) at 492 nm and measuring 
the emission at 518 nm. The Gen5 software was used. This software is capable of collecting 
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microplate data and conduct analysis after settle a range of excitation and emission wavelengths for 
the test.  
Protein samples were prepared individually in aluminum-coated eppendorfs containing 1X 
Phosphate Buffer Solution (PBS) pH= 7.6 freshly prepared. The use of PBS buffer enables a 
constant pH and osmolarity, but also ion concentrations in the samples similar to ones in the 
human body (isotonic). Moreover, using a buffer solution also prevents denaturation or other 
conformational changes in aptamer and protein samples. The 10X PBS was prepared dissolving 80 
g of NaCl, 2 g of KCl, 14.24 g of Na2HPO4.2H20, 2 g KH2PO4 in 800 mL distilled H2O. After adjusting 
the volume to 1 L with ultra-pure water, the PBS was autoclaved and stored at room temperature. 
Before the fluorescence measurements, 100 mL of fresh 1XPBS was prepared from the stock 
solution (10XPBS) and immediately used to prepare the protein samples.  
A 60 µl volume of purified proteins at increasing concentrations (0, 3, 10, 30, 100, 300, 
350 nM) was added to the 96-dark well plates, as well as 20 nM of fluorescein-labeled DNA/RNA 
(aptamer). The mixture was incubated at 25°C for 30 min in the dark (to avoid loss of fluorescence 
and interferences with the assay). Figure 9 illustrates the scheme of the samples in the 96-well 
plate for the fluorescence assays. 
 
 
 
 
 
 
 
 
 
 
Prior to incubation with proteins (human thrombin and osteopontin, and BSA (interferent)), 
the aptamer samples) were denatured at 95°C for 5 minutes to unfold the DNA/RNA strand. Then, 
they were cooled in ice for 5 minutes to block the DNA/RNA in its unfolded structure. Finally, the 
aptamers were left to cool down to room temperature (RT) for a residual slow annealing (Tran et al., 
2010; Zou et al., 2012).    
Figure 9 Scheme of the 96-dark well plate for the fluorescence measurements 
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Since during the course of the current work it was not possible to perform the fluorescence 
measurements in triplicate, mainly due to the amounts of samples that were available and to the 
costs of the proteins being studied, in order to compare results obtained with proteins from the 
same preparation mode (same batch), the same 96-dark well plate that was used to read the 
samples after 30 minutes of reaction, was reused to check the binding reaction after 1 and 4 hours. 
 
2.1.3. Fluorescence anisotropic measurements and dissociation constant (Kd) data fitting 
Due to the experimental difficulty in measuring the amount of free DNA aptamer, it is 
crucial that Kd is accurately determined through the use of the total DNA amount in the 
calculations. At large ratios of aptamer to ligand concentration, the total concentration of the ligand 
can be regarded as sufficiently small to be ignored. 
The fluorescence data along time were converted into aptamer:protein fluorescence and 
afterwards into concentrations. A non-linear fitting was conducted using the solver tool from excel in 
order to determine the Kd for TBA1 and TBA2. 
The set of equations (1 to 5) described below were used for the Kd determination. These 
involve the following parameters: FT, total fluorescence; FAPTNB, fluorescence of the aptamer not 
bound; and FCOMPLEX, fluorescence of the complex. As the one-to-one binding stoichiometry for aptamer 
binding to a protein can be written as: 
                                                                                                       (1) 
      [     ]   [       ]                                                                    (2) 
      {[     ]  [        ] }   [       ]                                (3) 
      [        ]    [       ]   [       ]                         (4) 
As in the equilibrium the total amount of DNA should be bound to protein, [APTBOUND] ≈ 
[COMPLEX], as a result, 
                                                   [       ]  
      [     ] 
   
                                          (5) 
where, “a” is null (“a” is the correction parameter applied in all fluorescence values when a 
null protein concentration is measured. In an attempted to determine this value it was assumed 
that the fluorescence data were corrected and related with the calibration curve of the aptamer 
involved); “b” is the coefficient between the emitted fluorescence and the aptamer concentration 
used in the experiment (only by the aptamer, i.e. when the protein concentration is null); and “c” is 
the fluorescence value that corresponds to an aptamer concentration of 20 nM. Several assays 
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were performed, in order to establish 20 nM as the final concentration of aptamer. However, the 
concentration range studied took into account studies carried by other authors (Gokulrangan et al., 
2005). 
2.2. Electrophoretic mobility shift assays (EMSA)  
The electrophoretic mobility shift assay (EMSA) is one of the most sensitive methods for 
studying the DNA-binding properties of a protein. This method can be used to deduce the binding 
parameters and relative affinities of a protein for one or more DNA sites, or for comparing the 
affinities of different proteins for the same sites. The protein-DNA complexes are separated from free 
(unbound) DNA by electrophoresis through a non-denaturing polyacrylamide gel.  
This method relies on the property that nucleic acid will migrate through an agarose or 
polyacrylamide gel matrix towards an anode upon application of an electric field. Through this 
approach, the protein retards the mobility of the DNA fragments to which it binds. Thus, the free 
DNA migrates faster through the gel than the DNA protein complex (Sosic et al., 2011) (Figure 10). 
 
 
 
 
 
 
 
 In a somewhat simplified view, the migration of DNA through a gel is governed by three 
primary factors, the molecular weight (and hence the charge) of the DNA, its three-dimensional 
shape, and the physical properties of the gel substrate (Ryder, Recht, & Williamson, 2008). In the 
study from Sosic and co-workers (2011), EMSA was performed to verify whether the chemical 
modifications introduced in TBA1 and TBA2 would affect aptamer/protein recognition. The results 
showed that the band corresponding to unmodified TBA2 aptamer in KCl 10 mM folds in G-
quadruplex shifts up and new bands with lower mobility, representing the TBA2-thrombin complex, 
appear in the upper part of the gel, as expected. 
  
Figure 10 Electrophoretic mobility shift assay representation. The gel shift assay consists of three key 
steps: binding reactions, electrophoresis and probe detection. Adapted from 
http://www.piercenet.com/media/EMSAOverview615x416.jpg. 
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2.2.1. Reagents 
TEMED (N,N,N′,N′-Tetramethylethylenediamine) (Sigma-Aldrich) was stored tightly sealed at 
4°C. Ammonium persulfate (APS) (Sigma-Aldrich) was stored in a desiccator at 4°C. APS was used 
in a 10% w/w solution to be used as a catalyst for the copolymerization of acrylamide and 
bisacrylamide gels. The polymerization reaction was driven by free radicals generated by a redox 
reaction in which TEMED (a diamine) was used as the adjunct catalyst. A 40% w/v acrylamide-
bisacrylamide solution for electrophoresis contain the proportion 37.5:1 of acrylamide: 
bisacrylamide (BIO-RAD) was prepared and kept at 4°C and protected from light until use. All 
reagents were purchased by Sigma-Aldrich. 
Tris-borate-EDTA (TBE) buffer is often used for gel electrophoresis in the analysis of DNA 
reactions. For the experiments, TBE 5X buffer was prepared, dissolving both 54 g Tris base and 
27.5 g boric acid (both from Sigma-Aldrich) in approximately 900 mL deionized water. Afterwards, 
20 mL of 0.5 M EDTA (pH 8.0) was added and the volume solution was adjusted to 1 L. Then TBE 
5X was stored at RT and used until precipitate was formed. Deionized purified (MILLIPORE, ELIX5) 
water was also required for the experiment and all the other reagents used were from acceptable 
molecular biology grade. Commercial petroleum jelly was used to seal the plates before the gel 
apparatus was assembled.  
All the complexes resultant from the ELISA assay were also used for the EMSA experiments 
as well.  
2.2.2. Equipment 
An electrophoresis power supply and a vertical electrophoresis apparatus were used. This 
apparatus includes glass plate spacers (1.0mm), well-forming combs, clamps and optionally, a gel-
casting stand.   
2.2.3. EMSA Analysis for Binding Complexes 
After 4 hours of protein and aptamer mixture incubation, a gel electrophoresis was carried 
out to confirm the formation of the complex protein:aptamer. The methodology used was adapted 
from Sosic et al. 2011 (Sosic et al., 2011). Briefly, the protein-aptamer complexes were resolved by 
a 12% non-denaturing acrylamide gel with 4% stacking-gel. The gels were prepared from the 
solutions described in Table 6.  
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      Table 6 Solutions for preparing resolving gels for NATIVE-PAGE gels 
12% Resolving Gel (for two gels) 4% Stacking Gel (for two gels) 
 % (v/v) mL % (v/v) mL 
Acrylamide Mix 40 3 40 0.225 
Glycerol 50 0.2 - - 
APS 10 0.075 10 0.03 
TBE 5X Buffer  1  0.6 
TEMED  0.00075  0.0003 
Water  5.2775  1.575 
Total Volume of Gel  5  3 
 
(Note: It is important that the gel solution (without TEMED) must be stirred at room temperature, under 
vacuum, until all bubbles are eliminated. The gel polymerization can then proceed by adding TEMED).  
While gels are polymerizing, samples from the 96-dark well-plate were collected. Samples were 
individually prepared in appropriate volumes, by pipetting 10 µL of each protein-aptamer mixture 
(from the previously ELISA described binding reactions) and add with 10 µL of bromophenol blue 
dye.  
After polymerizing, the 12% non-denaturing polyacrylamide gels were placed in the 
electrophoresis apparatus. TBE 1X was added to the top and bottom reservoirs. After removing all 
the bubbles that were trapped, 20 µL of each samples were loaded. Also, a 100 kb DNA marker 
(New England Biolabs) was used. Prior to loading, the marker was denatured at 95°C for 5 minutes 
and was cooled for 5 minutes extra to allow the visualization of the bands by naked eye. 
The electrophoresis was carried at 200 V constant voltage for about 1hour and 45 minutes. 
After running the gels, aptamer-protein complexes were stained with the fluorescent DNA binding 
dye Sybr®Safe (Invitrogen) (5 µl/ 50 ml TBE 1X) for 10 minutes at RT and the results documented 
by exposure of the dried gel to Chemidoc program (BioRad). 
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2.3. Immobilization Assay on Screen-Printed Electrode 
 
2.3.1. Apparatus 
Electrochemical analysis was performed at room temperature (RT) using an electrochemical 
analyzer PGSTAT-10 Autolab (Ecochemie). The screen-printed gold electrode (SPE) was composed 
of a working, reference and counter electrode. The working electrode had a diameter of 0.8mm 
(DropSens, S.L., Spain). 
2.3.2. Reagents and solutions 
Thrombin-binding DNA sequences entitled as unmodified 15-mer thrombin binding aptamer 
1 (TBA1): 5’-GGT TGG TGT GGT TGG-3’ and unmodified 29-mer thrombin binding aptamer 2 (TBA2) 
: 5’-AGT CCG TGG TAG GGC AGG TTG GGG TGA CT-3’. Both aptamers have been designed to 
possess in the 5`end a biotin molecule, since this is a typical motif with high affinity to avidin that 
will be used to functionalize the surface of the electrode (immobilization step). The aptamers were 
synthesized by IDT Integrated DNA Technologies (Munich, Germany). 
The protein used was of analytical grade highly purified. Thrombin from human plasma 
(T6884) was purchased from Sigma-Aldrich (Saint Louis, MO, USA). Thrombin samples were 
prepared in PBS at pH 7.4 (Z. Liu et al., 2009).Thrombin samples were prepared from a 20 μM 
aliquot at different concentrations (0.025, 0.05, 0.5, 1 and 50 nM).  
Regarding the reagents used, the 3,3`-dithiopropionic acid-di(N-succinimidylester) (DSP) 
was purchased from Fluka and used in a 1 mg/mL concentration. Dimethyl sulfoxide (DMSO) 
required for the preparation of DSP was purchased from (> 99%, Fluka). The PBS stock solution 
(0.1M) was prepared as described in the previous assays.  
As described in Wu et al.,  2011 (Wu, Zheng, Shen, & Yu, 2009), the redox solution was 
prepared with a final concentration of 5mM K4[Fe(CN)6]:K3[Fe(CN)6] in 100 mM. The following 
amounts were weighed, 215 mg of Fe(CN)6]4-, 165 mg of Fe(CN)6]3- (both from Acròs Organics) and 
75 mg of KCl (Panreac), and further dissolved in 100 mL of PBS 1X. After homogenizing the 
solution, the flask covered by aluminum foil containing the redox probe was degassed in an 
ultrasound sonicator bath (Tesla) for 15 minutes.  
In the regeneration step, 7M of urea was used (purchased from National Diagnostics). 
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2.3.3. Aptamer immobilization onto the gold electrode surface by avidin-biotin methodology 
To immobilize the aptamer onto the gold surface, as shown in Figure 11, no cleaning step 
was required. The first step of the immobilization procedure was to confirm the cyclic 
voltammogram (CV) curve. Experimentally, the three electrodes were etched with 60 μL of redox 
solution [Fe(CN)6]3-/4- under an optimized electric potential within -0.5 to 0.5V and a step potential of 
0.05V/s. Then, the electrode was washed with PBS and left to dry at RT. Subsequently, the gold 
surface was modified with 1 μl of 4 mM DSP. This procedure lasted 15 minutes, RT. After washing 
again the electrode with PBS, the working electrode was washed three times with 1mg/mL of the 
avidin solution and then it was incubated at 4˚C with this protein approximately 23 hours. 
After avidin incubation, the electrode was washed twice with PBS and was incubated for 
1hour in BSA (0.025%) solution. This method was used to block free binding sites on the activated 
electrode surface. The electrode was again washed with PBS and left to dry at RT until the next 
immobilization step. 
Before the immobilization, proper folding of the aptamer has been provided by heating it to 
95˚C for 5 minutes to unfold the DNA strand. Next, the aptamer was cooled in ice for 5 minutes (to 
block the DNA in its unfolded structure), and finally it was left to cool to RT (for a residual slow 
annealing) (Tran et al., 2010) (Zou et al 2011) and then cooled in ice for 10 minutes. After 
conditioning the electrode with the aptamer solution (1μM biotinylated-aptamer solution) for 30 
minutes at RT, the electrode was again washed with PBS and it was carefully cleaned before 
analysis. 
Thereafter, on SPE it was performed cyclic voltammetry (CV) analysis with 60 μL of the 
redox solution to characterize the bioaffinity immobilization of the aptamer to the gold electrode 
using the analyzer.  All the steps involved in aptamer immobilization are described in Figure 11. 
 
I 
 
 
 
 
Figure 11 a) A schematic diagram of a TBA aptamer immobilized on the working electrode region of 
a screen-printed electrode chip. b) Scheme of signal off system through interference in the electron 
transfer. Adapted from Kim, Y. J. et al., 2010 
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It presents the detailed detection process of the electrochemical aptasensor for human 
thrombin. The screen-printed electrode (SPE) is first modified by a homogeneous film of 
DSP/avidin/BSA. This step leads to an increase of the effective surface area of the electrode and 
provides an enhanced loading surface for the subsequent aptamer immobilization. 
Afterwards, the electrode was used immediately to measure different protein (thrombin) 
concentrations; otherwise it was kept at 4 ˚C for less than 1 week until further use (Hianik et al., 
2007). 
 
2.3.4. Experimental detection of Thrombin 
Human thrombin samples were prepared in PBS 1X pH 7.4. For protein detection, 1 µL of 
each thrombin sample concentration was dropped on working electrode at RT for 30 minutes. After 
carefully washing the SPE with PBS 1X and left it to dry, 60 μL of the redox solution was placed on 
the sensor surface until all the three electrodes were immersed. Cyclic voltammetry was performed 
and the correspondent voltammograms were obtained. The experimental setup is characterized in 
Figure 12. 
 
 
 
 
 
2.3.5. Electrode sensor-surface regeneration 
To dissociate thrombin and regenerate the aptamer layer, the electrode was incubated with 
1 µL of 7M urea buffer and incubated for 2 minutes. Then, the SPE was washed with PBS and CV 
curve was performed. This process of surface regeneration should not compromise the sensitivity of 
the aptamer layer and should allow testing the same aptamer layer with compound concentrations 
of thrombin (Y. Liu, Tuleouva, Ramanculov, & Revzin, 2010).
Figure 12 Electrochemical sensing of thrombin using thrombin binding aptamer (TBA) 
functionalized gold electrode. Taken from: Cai et al., 2006 
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3. Results and discussion 
The results gathered in this thesis are presented and discussed in this chapter and are divided in 
two main sections: binding assays and development, optimization and validation of an aptasensor 
for the detection of thrombin. 
3.1. Binding Assays 
3.1.1. Fluorescence: Effect of the Labeling Strategy. Predictions & Observations. 
Binding assays were conducted with 3 different fluorescein-labeled aptamers: OPN-R3FAM, 
TBA1FAM and TBA2FAM. OPN-R3FAM is an aptamer that has been reported to bind specifically to 
human osteopontin (Zhiyong Mi et al., 2009); TBA1 is a 15-mer DNA aptamer which binds exosite I 
of thrombin (Fibrinogen Binding Site) (Tasset, Kubik, & Steiner, 1997); while TBA2 is a 29-mer DNA 
aptamer binding to exosite II of thrombin (Heparin Binding Domain) (D. W. Huang et al., 2010; 
Sosic et al., 2011). 
It is noteworthy that the 6-FAM- labeled aptamer is a relatively small molecule compared to the 
size of the proteins that they target. It is expected that when the aptamer binds to the protein, the 
increase of the overall size and molecular weight of the complex leads to a pronounced slowdown of 
the fluorescein molecule rotation. The slower rotational diffusion would result in a lower ability of the 
fluorescein molecule to depolarize the incident polarized excitation. Consequently, the anisotropy of 
the emission would also increase to reflect the slower motion of the dye itself.  
In these assays, the 3 aptamers were incubated with four different proteins, human recombinant 
Osteopontin (rhOPN), bovine OPN (bOPN), serum bovine albumin (BSA) and human thrombin 
(hThr). According to NCBI, bOPN is known to have 55% homology with hOPN. Therefore, it is a 
useful compound to be used as a model to evaluate the OPN-R3FAM specificity. Further on, assays 
should be conducted with rhOPN to evaluate an even higher specificity of the aptamer, i.e. to 
confirm if it can distinguish between human and bovine OPN. Besides, Beausoleil et al. (2011) 
reported that OPN is cleaved by thrombin. Therefore, the assessment of the potential binding 
between OPN-R3FAM and thrombin will also enable the confirmation of the aptamer specificity. The 
same approach was used for TBA1 and TBA2 characterization. 
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3.1.1.1. ELISA`s method validation 
Human OPN is a protein usually overexpressed in tumors and serum of women with ovarian and 
breast cancer (Rodrigues, Lopes, Sousa, Vieira, & Milanezi, 2009) and it is found in concentrations 
at the nanomolar  level (Kadkol et al., 2006). This protein is a potential therapeutic target for the 
regulation of cancer metastasis, thus the RNA aptamer technology targeting OPN may represent a 
clinically viable diagnostic tool to validate the method for assessing the formation of aptamer-protein 
complexes. 
In the experiments, the OPN-R3FAM aptamer concentration was fixed at 20 nM as previously 
established in other experiments. Moreover, since the results obtained with different incubation 
times showed similar profiles, the following analyses were conducted with the shorter binding 
reaction time, meaning 30 minutes. The binding between 20 nM of OPN-R3FAM and rhOPN was 
evaluated through fluorescence anisotropy analysis as illustrated in Figure 13.  
 
       
An appreciable increase of fluorescence anisotropy was found after incubating the protein with 
the aptamer, thus indicating the formation of the aptamer–rhOPN complex. After the formation of 
the protein-aptamer complex no further increases in the fluorescence should be observed, because 
all major fluorescent components are already bound to the aptamer. 
The initial nonlinear fitting analysis of the fluorescence data using the binding model described 
in the Materials and methods section showed that the aptamer binding site on each target molecule 
is a one-to-one binding model. The assumption that one target molecule binds to each aptamer, 
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Figure 13 Single binding assay for OPN-R3FAM and hOPN. The aptamer concentration used was 
20 nM, the binding reaction time was 30 min and the fluorescence was recorded at 518 nm 
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significantly improves the fit of the data, however further information on OPN will be necessary to 
conclude about this. The non-linear fitting of our data led to a Kd value around 5.85 nM for 30 
minutes of incubation which is better than the one reported by Mi and co-workers (2009). In their 
study, RNA electrophoretic mobility assays were used to characterize the aptamer sequence of OPN-
R3 against rhOPN, and a Kd value of 18 nmol/l was obtained. It is difficult to determine the reasons 
for the differences obtained for the aptamer since different methodologies were used to evaluate the 
formation of the aptamer-protein complex. 
 
 
           
A major advantage of the fluorescence assay is that it does not present interference from non-
specific interactions between proteins and the aptamer probe. To assure its practical use, any 
protein probe should be able to distinguish between its target and other interfering proteins. While 
the aptamer sequence has been reported to be highly selective for OPN, it is still important to test 
its selectivity by using other interfering proteins in the fluorescence assay. Furthermore, it is relevant 
to demonstrate that the fluorescent label and the fluorescence method will not affect in anyway the 
selectivity of the aptamer probe for OPN. For that purpose, several experiments were carried out in 
which the aptamer solutions were added to several common extracellular proteins, such as BSA, 
thrombin and bovine OPN (an homologous of the human OPN) and fluorescence changes were 
recorded. These changes were then compared to the fluorescence change caused by human OPN. 
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Figure 14 Plot 20nM OPN-R3FAM fluorescence responses at 528nm versus protein concentrations 
(bovine osteopontin, bOPN, bovine serum albumin, BSA, human blood thrombin, Thr and human 
osteopontin, rhOPN) in the standard phosphate buffer 
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As shown in Figure 14, it was found that the aptamer sensor yielded very weak fluorescence signals 
in response to other proteins such as BSA and thrombin, which contrasted with the pronounced 
fluorescence response to rhOPN. Moreover, the specificity of the aptamer to rhOPN could be further 
confirmed from the assays conducted with bovine OPN (homologous to the human OPN).  
The results herein gathered revealed that the aptamer is selective for the human OPN, thus 
supporting its applicability for medical diagnosis. On the other hand, the fluorescence method was 
found to be easy, simple and accurate for the evaluation of the aptamer-protein complex formation. 
This procedure is straightforward and could be very simply used as an alternative to other existing 
techniques involving the use of aptamers as recognition elements (Z. Cao, 2002; Gokulrangan et 
al., 2005; Nutiu & Li, 2004; Stojanovic, Prada, & Landry, 2000; Zou et al., 2012; Zuo, Xiao, & 
Plaxco, 2009). 
 
3.1.1.2. Development and optimization of ELISA`s method  
To demonstrate the utility of the methodology implemented, the same method was applied to 
human thrombin, which plays an important role in the coagulation cascade and hemostasis. The 
thrombin binding aptamer (TBA) folds into a well-defined quadruplex structure and binds to its 
target with good specificity and affinity: TBA1FAM and TBA2FAM were used to perform the FA 
experiments. Interferences by other proteins were also evaluated.  
In the experiments conducted with both TBA1FAM and TBA2FAM aptamers, the fluorescence 
profile revealed an increasing binding activity through fluorescence quenching as illustrated in 
Figures 15 and 16, respectively. These results indicate the specificity and affinity of the aptamers 
for both thrombin exosites. However, TBA1FAM displays higher fluorescence values and better 
stability after the saturation point has been reached. Furthermore, a linear response is reached at a 
concentration of 30.11 nM of human thrombin, which suggests that further studies should be 
conducted with this protein to evaluate possible differences in the binding affinity constants in 
shorter protein concentration intervals.  
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               The evaluation of possible unspecific binding of TBA1FAM and TBA2FAM was 
conducted using the same proteins that were previously used for the OPN-R3FAM aptamer. 
Similarly, these proteins were used as negative controls. Figures 17 and 18 illustrate the results 
obtained for TBA1FAM and TBA2FAM, respectively. In these experiments it was assumed that TBA 
is in a conformational equilibrium between its unfolded state and the folded, binding-competent G-
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Figure 16 Fluorescence binding studies for TBA2FAM (20 nM) with concentrations from 0 to 376.31 
nM of hThr, after 30 minutes incubation 
Figure 15 Fluorescence binding studies for TBA1FAM (20 nM) with concentrations from 0 to 376.31 
nM of hThr, after 30 minutes incubation 
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quartet conformation. Since thrombin binds only the G-quartet conformation, the target protein 
drives the equilibrium towards this state, thereby producing the observed signal. From the above 
mentioned figures, TBAFAM-aptamers do not bind specifically to BSA or to either of the human or 
bovine OPN evaluated. Furthermore, as OPN has a cleavage site to thrombin, it could have some 
binding affinity for thrombin DNA aptamers. Surprisingly, fluorescence values seemed more stable 
for BSA binding assays than for the OPN ones. 
 
Figure 17 Plot 20nM TBA1FAM fluorescence responses at 528nm versus protein concentrations (bovine 
osteopontin, bOPN, bovine serum albumin, BSA, human blood thrombin, Thr and human osteopontin, 
rhOPN) in the standard phosphate binding buffer, after 30 minutes incubation 
 
Figure 18 Plot 20nM TBA2FAM fluorescence responses at 528nm versus protein concentrations (bovine 
osteopontin, bOPN, bovine serum albumin, BSA, human blood thrombin, Thr and human osteopontin, 
rhOPN) in the standard phosphate binding buffer, after 30 minutes incubation 
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Again, the results herein obtained revealed a good selectivity of the TBA aptamers which turns 
ELISA into a valuable method to assess the specificity of aptamers for their target proteins so that 
they could be used in electrodes to develop detection aptasensors. Despite its long use for many 
biotechnological applications, ELISA is currently being used as a pioneering concept (Chang, Tang, 
Wang, Jiang, & Li, 2010; H. Chen et al., 2013; Jin, Bai, & Li, 2010; Paborsky et al., 1993; W. 
Wang, Chen, Qian, & Zhao, 2008).  
 
3.1.1.3. Dissociation constant (Kd)  
The analysis of affinity assays conducted with thrombin using a wide range of measured 
concentrations could be achieved with TBA affinity probes. These TBA aptamers bind to thrombin 
with significantly different equilibrium constants (Kd). The dissociation constant (Kd) is a parameter 
that reflects the amount of complex formed for a specific recognition element, i.e. for each TBA, 
using a specific detection method. In addition, the smaller the Kd, the stronger the link between the 
aptamer and the protein will be. 
Initial non-linear fitting analysis of the fluorescence data obtained with the two aptamers (as 
described in the Materials and Methods section) demonstrated that the model 1:1 was adequate to 
fit the results (Table 7). 
Table 7 Dissociation constants (Kd) for TBA1 and TBA2 with different protein targets for two different 
incubation times 
Kd value (nM) Incubation 
time 
hThr rhOPN bOPN BSA 
TBA1FAM 30 min 
 
1.820 * * * 
4 h 
 
1.071 * * * 
TBA2FAM 30 min 
 
0.867 DNC DNC * 
4 h 
 
1.778 DNC * DNC 
DNC – does not converge, *it makes no sense to calculate the Kd value for proteins for which the aptamer was not specific. 
Therefore, the calculated values are merely obtained by fitting approximations. Designations: bovine Osteopontin (bOPN), bovine 
serum albumin (BSA), human blood thrombin, (hThr) and human Osteopontin (rhOPN). 
The non-linear fitting of the data enabled the estimation of the Kd values for each TBA 
aptamer, when the TBA-thrombin complex was formed.  
TBA1 was the first DNA thrombin binding aptamer to be selected and its dissociation 
constant was previously reported to be around 26 nM (Bock, 1992). Furthermore, this aptamer was 
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described as a potential anticoagulant agent, and presents enzymatic inhibitory functions that are 
required for thrombin-mediated coagulation since it interacts with the fibrinogen-binding exosite-1 of 
thrombin (Chiu & Huang, 2009). Most studies conducted with TBA1 aptamer reported Kd values 
around 25 nM (Hamula, Guthrie, Zhang, Li, & Le, 2006). However, in the current study (Table 8), a 
Kd value of 1.820 nM was reached. This result suggests that the TBA1FAM has a better specificity 
for thrombin than the TBA1 aptamers used in the other reported studies. Comparing Kd values for 
TBA1 aptamer using fluorescence anisotropy (Table 2) with the ones described by Hamaguchi and 
collaborators (2001) it can be concluded that the fluorescence measurement was more sensitive 
than their approach. In their research, using an aptamer-beacon and the fluorescence as the 
detection technique, they obtained a Kd value of 10 nM. 
Regarding the TBA2, it was first described by Tasset et al. (1997) that reported its high 
affinity to thrombin, Kd = 0.5 nM. As can be seen in Table 7, the value estimated for this aptamer in 
the current work is close to the Kd value previously reported, suggesting that TBA2 behaves in a 
more predictable and constant manner,  and also that the fluorescence method is as sensitive as 
the methods used in other studies (Tasset et al., 1997).  
An attempt to fit the data obtained in the assays conducted with interfering proteins was 
done. However, since the thrombin aptamers are non-specific to those proteins, no protein-aptamer 
complexes were formed, and therefore no consistent changes could be observed in the 
fluorescence, as expected.  
3.1.1.4. EMSA as an analytical technique for detection of the formation of the aptamer-
protein complex by EMSA  
3.1.1.4.1. Validation of the TBA1FAM and TBA2FAM aptamers binding to thrombin by EMSA 
Before conducting the EMSA binding studies, several optimization steps were performed to 
guarantee the best gel resolution and detection limit of the samples. These optimization steps 
consisted in evaluating several operational parameters that include the gel running temperature 
(4ºC and room temperature); the presence or absence of stacking gel; and different TBE 
concentrations used in the gel (TBE 0,5X or TBE 5X).  
The best conditions for EMSA binding assays were determined as: presence of a 4% 
stacking gel; use of TBE 5X for gel preparation; and gel running at room temperature. The EMSA 
studies were conducted with the FAM labeled aptamers, namely TBA1FAM and TBA2FAM. 
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Calibration curves were conducted for both aptamers and a significant aptamer concentration of 
0,8 µM was necessary to enable the samples detection (Figure 19). 
 
 
 
 
 
 
 
                
3.1.1.4.2. Optimization of the method to TBA1FAM and TBA2FAM aptamers binding to 
thrombin by EMSA  
After measuring fluorescence in the ELISA, 10 µL of each binding reaction mixture was 
used to perform the EMSA analysis. In these experiments, it was expected that starting from lower 
thrombin concentrations the band correspondent to the free aptamer would gradually disappear, 
and at the same time the band with lower mobility corresponding to TBA-thrombin complex would 
appear (Figure 20). However, for unknown reasons, the presence of the aptamer-protein complex 
(low mobility band) could not be detected for both thrombin aptamers. This could be due to the fact 
of being operating in conditions below the limits of detection of the method. In addition, using the 
samples from ELISA assays to prepare the EMSA experiment will dilute the samples even more. 
Sosic et al. (2010) found that the minimum protein concentration required to form the 
aptamer:protein complex was about 10 μM. In the current work, protein concentrations lower than 
this reference value was used. Following this assumption it is expected that there is no sufficient 
amount of protein in order to see it in the gel. 
Figure 19 Electrophoretic Mobility Shift Assay (EMSA) using different concentrations of a) 
TBA1FAM and b) TBA2FAM under the conditions described in Materials and Methods section. 
Binding reaction mixtures were applied on a 12 % non-denaturing gel containing 5X TB TBE 
buffer. The mobility of free aptamers, stained by SybrGreen Safe®, was detected using the 
Chemidoc System. 
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Figure 21 shows the conducted assays with TBA1FAM and TBA2FAM with interfering 
proteins (BSA, rhOPN and bOPN) demonstrated that no binding occurred between these proteins 
and the aptamers, which is in accordance with the previous fluorescence results. Nevertheless, the 
overall results gathered in the EMSA assays were inconclusive since no protein-aptamer complexes 
could be observed in the experiments in which human thrombin was used. Furthermore, it is 
important to mention that the gels were also stained using the silver nitrate method. However, it 
was still not possible to observe any aptamer-protein complex in the gels, which may be the result of 
the low protein concentrations kept concerning the dilutions made for EMSA proceedings. 
 
Figure 20 Electrophoretic Mobility Shift Assay (EMSA) of a) TBA1FAM and b) TBA2FAM 
under increasing concentrations of human thrombin, collected from ELISA assays. Binding 
reaction mixtures were applied on a 12% non-denaturing gel containing 5X TBE buffer. The 
mobility of free aptamers, stained by SybrGreen Safe®, was detected using the Chemidoc 
System. 
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3.2. Development, optimization and validation of an aptasensor for thrombin 
The progress of the Human Genome Project has generated substantial interest in the use of 
nucleic acid technologies to develop sensors capable of identifying human proteins involved in 
crucial biological processes. The challenges for biomedical researchers include the characterization 
of the biological function of these proteins. Intense research activities are being carried out 
worldwide to apply this knowledge for the design and engineering of specific, fast, simple, and 
Figure 21 Electrophoretic Mobility Shift Assay (EMSA) of a) TBA1FAM and b) TBA2FAM 
under increasingly concentrations of interferents, harnessed from ELISA assays. Binding 
reactions were applied on a 12% non-denaturing gel containing 5X TBE buffer. The 
mobility of free aptamers, stained by SybrGreen Safe®, was detected using the 
Chemidoc System. 
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sensitive electrochemical aptasensors for medical diagnostics applications (Hong et al., 2012; Mir 
et al., 2006). 
3.2.1. Optimization of experimental conditions for aptasensor 
Several parameters were further considered to optimize the aptasensor regarding its 
sensitivity and accuracy including the TBA-thrombin incubation and the sensor operating conditions.  
3.2.1.1. Optimization of the sensor conditions 
The evaluation of different scan rates is presented in Figure 22. The electrode was 
incubated with 60 µl of the redox solution and 4 different scan rates were tested, namely 0,01 V/s; 
0,05 V/s; 0,1 V/s and 1 V/s. After analyzing the data, the best scan rates, i.e. the ones that 
presented a lower inconsistency between 5 consecutive scans were 0,01 V/s and 0,05 V/s. In the 
present work the scan rate of 0,05 V/s was chosen since it presented a good compromise between 
scan reproducibility and analysis speed. 
 
 
 
 
 
 
 
 
 
 
In order to avoid any interference related with the preparation of the redox solution, a 
routine preparation protocol was developed. In fact, when working with aptamers the addition of 
high concentrations of salt (often 2 M NaCl or KCl) can cause the disruption of the hydrogen bonds 
and electrostatic interactions that are responsible for most of the aptamer-target association. In 
addition, it is well-known that for the optimal performance of electrochemical detection methods, 
the presence of counter-ions in the medium is desirable. However, it has been demonstrated that 
Figure 22 Cyclic voltammetry scan rate optimization results (0,01; 0,05; 0,1 and 1 v/s) 
using a [Fe(CN)6]−3/−4 redox probe 
      Results and discussion 
50 
 
the presence of certain ions can induce the folding of some aptamers in a manner similar to their 
molecular targets, as is in fact the case with TBA in the presence of KCl (A. E. Radi et al., 2006). 
Therefore, following a daily protocol in which the concentration of each reagent is controlled 
minimizes possible interference in the signals obtained by CV. 
 
3.2.1.2. Optimization of the incubation conditions 
The incubation time of thrombin with the aptamer was found to have a major impact on 
the formation of the aptamer-target complex. Several studies showed that a time range between 30 
and 40 min is enough to ensure quenching between the aptamer and the particular protein (Ji et 
al., 2012; Khezrian, Salimi, Teymourian, & Hallaj, 2013; S. Xie et al., 2012). Therefore, 30 min 
incubation time was selected to perform binding assays in the current work. 
Thrombin-aptamers prefer to adopt a G-quarter structure when binding to thrombin (Ho & 
Leclerc, 2004). Incubation conditions, such as the pH value and temperature have a great impact 
on the formation of the G-quarter structure (Suprun et al., 2008). Some authors showed that the 
protonation of guanine groups of the aptamer sequence occurs at pH values below 7.0, while an 
increasing in the aptamer negative charge was seen for pH values above 8.0, thus leading to the 
disassemble of the G-quartets of aptamer (Zhao et al., 2011) Based on this, a redox solution 
containing 5 mM [Fe(CN)6]4-/3- in 100 mM KCl prepared in PBS, pH 7.4 was selected for the SPE 
preparation and detection of hThr in the current study. 
The effect of the incubation temperature is also a crucial point to consider. Tang and 
Shafer (2006) suggested that thrombin does not bind the aptamer when the incubation 
temperature approaches or surpasses its melting temperature (46◦C). Other authors reported that 
the highest signal could be obtained with an incubation temperature of 4◦C, in which the G-quarter 
structure was stable (Eva  Baldrich, Restrepo, & O′Sullivan, 2004). However, in the current study 
the immobilization assays were conducted at RT since the fluorescence binding assays were 
previously performed in those conditions.  
 
3.2.2. Design of an electrochemical aptasensor 
TBA1 (15-mer) or TBA2 (26-mer) aptamers were modified with biotin at 5`- end as the 
following sequences:  (TBA1-biotin): 5’-biotin-GGT TGG TGT GGT TGG-3’ and (TBA2-biotin): 5’-biotin- 
AGT CCG TGG TAG GGC AGG TTG GGG TGA CT-3’. These aptamers are then attached individually in 
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different SPE`s via biotin- avidin binding. This bioaffinity method facilitates the immobilization of 
TBA on a SPE without losing its binding properties. 
In a study conducted by Diculescu et al., (2010), it has been shown that in the presence of 
alkali metals, such as potassium ions presented in the phosphate buffer solution, TBA forms an 
antiparallel intramolecular quadruplex consisting of two G-quartets connected by two TT loops and 
one TGT loop. The formation of the quadruplex structure plays an important role in binding to 
thrombin. Besides, due to its low cost and good redox characteristics, potassium ions were used as 
electrochemical indicator in our proposed system.  
A redox couple solution composed of 5 mM [Fe(CN)6]4-/3- in 100 mM KCl was used to 
characterize the electrochemical behavior of the bare sensor by cyclic  voltammetry (CV). It could 
be observed the binding of a quasi-reversible and well-defined redox peak from [Fe(CN)6]4-/3- (dark 
blue voltammogram). After the electrode modification with DSP, avidin and BSA the current 
responses of the SPE were significantly lower than that of the bare electrode, which suggested that 
these modifications could greatly promote the electron transfer. After the immobilization of TBA-
biotin, the response was clearly reduced due to the electrostatic repulsion between [Fe(CN)6]4-/3- and 
the negatively charged aptamer (orange curve). The resulting voltammograms are illustrated in 
Figure 23.  
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Figure 23 Cyclic voltammograms for a thrombin TBA2 aptasensor regarding the [Fe(CN)6]−3/−4 redox 
probe: SPE control (voltammogram to the electrode itself), After DSP (voltammogram after DSP 
modification), After Avidin (voltammogram after Avidin incubation, After BSA (voltammogram after 
BSA blockage), TBA2-biotin immobilized (voltammogram after aptamer immobilization)  
      Results and discussion 
52 
 
3.2.3. Electrochemical detection of thrombin using the aptasensors TBA1-biotin and TBA2-
biotin 
CV analysis were conducted against a series of hThr concentrations ranging from 0.025 nM 
to 50 nM using an SPE in which 1 μM TBA1-biotin aptamer  was immobilized. The concentration-
dependent decrease of the current was observed (Figure 24).  
From Figure 24 it could be seen that TBA1-biotin was not able to describe the current 
variations as a function of the thrombin concentration. Further experiments were conducted in order 
to overcome this issue and improve the thrombin detection. 
 
 
Figure 24 Electrochemical analysis of human thrombin hThr using modified TBA1-biotin-aptamer - 
immobilized on screen-printed electrode chip: a considerable current drop occurred by the treatment of hThr 
in a range of 0.025 nM–50nM from cyclic voltammetry; scan rate: 0.05V/s with a step potential of -0.5V to -
0.6V/s, using 5mM [Fe(CN)6]4-/3- in 100mM KCl prepared in PBS, pH 7.4 
 
For that purpose, the concentration of aptamer used for immobilization was reduced from 
1μM to 0.5 μM of TBA1-biotin, and only two different hThr concentrations were tested, as illustrated 
in Figure 25.   
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Figure 25 Electrochemical analysis of human thrombin (hThr) using modified (0.5 μM) TBA1-biotin-aptamer - 
immobilized on screen-printed electrode chip: a considerable current drop was occurred by the treatment of 
hThr in a range of 0.05 nM and 50nM from cyclic voltammetry; scan rate: 0.05V/s with a step potential of -
0.5V to -0.6V/s, using 5mM [Fe(CN)6]4-/3- in 100mM KCl prepared in PBS, pH 7.4 
 
However, the current drastically decreased with a thrombin concentration of 0.025 nM hThr 
and this was taken as a background signal. The results suggest that the aptamer gets saturated at 
very low thrombin concentrations and this precludes the use of TBA1-biotin aptamer in the next 
recognition steps. Neither is necessary to note that the concentration of 50 nM aptamer is already 
saturated and out of the detection range. 
On the other hand, TBA2-biotin exhibits a reduction peak increasingly smaller upon 
thrombin addition from a concentration above 50 nM even if the linearity was reached between 0.5-
50 nM of thrombin concentration (Figure 26). For this aptamer the current change as a result of the 
thrombin concentration was found to be saturated at 0.05 nM of hThr.  
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Figure 26 Electrochemical analysis of human thrombin (hThr) using modified TBA2-biotin-aptamer - 
immobilized on screen-printed electrode chip: a considerable current drop was occurred by the treatment of 
hThr in a range of 0.025 nM–50nM from cyclic voltammetry; scan rate: 0.05V/s with a step potential of -
0.5V to -0.6V/s, using 5mM [Fe(CN)6]4-/3- in 100mM KCl prepared in PBS, pH 7.4 
 
Binding Thr to the aptamer immobilized on the SPE surface may have affected the rate of 
electron flow produced from the redox reaction between the two reagent of the redox probe 
([Fe(CN)6]4-/3-). Therefore, the decrease in current after hThr incubation was associated to the specific 
interaction between aptamer and hThr that influenced the current. Studies on the interaction 
between aptamers and small molecules indicated that low-molecular targets are often pocketed into 
the folded aptamer structure, and it is difficult to perform a sandwich assay. A simple single-site 
binding assay is generally limited for the development of a sensitive EC aptasensor for small 
molecules since the electron transfer resistance or current changes due to the small target binding 
is usually low when compared to macromolecules like proteins. Binding thrombin to its aptamer 
leads to a decrease in the current due to interference with the electron flow. Therefore, in this study, 
it is believed that hThr induced the folding of the aptamer through the formation of a stem-loop 
structure, which probably induced the observed changes in the electrostatic property (Xiao et al., 
2005). 
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3.2.4. Determination of the SPE linear response range for the detection of thrombin 
The analytical performance of the aptasensor for thrombin was assessed under the optimal 
experimental conditions above mentioned. As shown in Figure 26, the electrocatalytic currents 
decreased with the increase of thrombin concentrations. Plotting the current response versus the 
thrombin concentration (Figure 26), it was possible to realize that the sensor was answering 
accordingly to thrombin concentrations. However, a linear response range for the detection of 
thrombin, it was only obtained for thrombin concentrations ranging from 0.5 to 50 nM, as shown in 
Figure 27. 
 
Figure 27 Thrombin concentration versus oxidation peak. The concentration of the aptamer employed during 
sensor fabrication was 1 μM. The incubation time was 30 minutes at RT  
  
An equation that describes the linear response was defined as follows:i(A)= 1e-8 [hThr] + 5e-6 
where i is the current response in relation to the oxidation peak and [hThr] is the thrombin 
concentration. The correlation coefficient is 0.9853 which indicated a good fitting of the 
experimental data by linear regression. Furthermore, it was found that the low detection limit was 
0.025 nM when in (Frense et al., 2013) it was referred that thrombin concentration in blood is 
normally around 0.01 nM.  
The results herein gathered showed that the thrombin aptasensor for thrombin detection 
presents a higher sensitivity, but lower detection limit, as compared with other reported methods in 
Table 4. In addition, after technical refining, it is believed that this aptasensor could be used for 
further thrombin detections to assess aptasensor performance. 
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3.2.4.1. The selectivity of the aptasensor 
The specificity performance of the aptamer-based assay for thrombin was further studied in 
this work. For that purposed, three interfering proteins were tested instead of thrombin using the 
same experimental procedure. These interfering proteins are either abundant proteins in serum 
(e.g., BSA) or analogous to the thrombin such as bovine Osteopontin (bOPN) and human 
Osteopontin (hOPN). Comparison of the CV responses of the biosensor were performed when 
exposed to hThr (50 nM), hOPN (50 nM), BSA (50 nM) and bOPN (50 nM), though, the 
regeneration step was not accomplished, considerations about the selectivity of the aptasensor 
cannot be done. 
 
3.2.4.1. Sensor regeneration and reusability 
Similarly to other aptasensors described in the literature, the thrombin aptasensor herein 
developed should be prone to regeneration and reusable. Several known regeneration reagents 
would be evaluated including 6 M guanidine hydrochloride (Xiao et al., 2005), 7 M urea buffer (Y. 
Liu et al., 2010), 2 M NaCl, 10% SDS and 1 M HCl (A. E. Radi et al., 2006).  
However, the regeneration step was only tested with 7 M urea buffer for 2 minutes.The 
regeneration steps for the removal of hThr from the TBA2-aptasensor were not effective. No recovery 
could be observed given the oxidation peak after hThr detection. Studies developed by Radi and 
coworkers used a molecular beacon aptasensor by simply unfolding the aptamer in 1.0 M HCl. The 
aptasensor could be regenerated for 25 times no loss in electrochemical signal upon subsequent 
thrombin binding (A. E. Radi et al., 2006). 
To sum up, given the importance of hThr as a clinical marker in the diagnosis of pulmonary 
metastasis and  when searching for anti-coagulants and antithrombotic agents to interfere with 
blood coagulation, the ability to selectively detect hThr molecules in the presence of overabundant 
non-specific proteins augurs well for future uses of this aptasensor in clinical diagnostics (Chiu & 
Huang, 2009). Compared to antibody-based affinity biosensors, aptasensors provide the advantage 
of being chemically stable. The chemical stability of nucleic acids ensures that aptasensors may be 
regenerated under conditions that disrupt aptamer-protein complex; however with TBA2-biotin this 
regeneration buffer does not remain advantageous. 
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4. Conclusion 
A new strategy to convert efficiently the aptamer-target recognition event into a measurable 
signal was described in the present work by introducing an fluorescent label reporter into the 
standard thrombin aptamer sequences. The extended aptamers seem to maintain the binding 
properties of the original sequences and preserve its high affinity and selectivity. An imaging system 
was used to measure fluorescence, thus enabling the determination of anisotropy changes in 
multiple samples. The fluorescence detection methods allows rapid and efficient formation of the 
aptamer-protein complex allowing this bond measure and determine the dissociation constants that 
are one important feature of aptamers which were taken into consideration for the construction of 
the aptamer. Fluorescence anisotropy technique has the unique ability of effectively detecting 
protein interactions with other molecules. 
The idea of coupling a fluorophore to the aptamer enabled the detection of the aptamer-
protein complex formation and the further determination of the binding dissociation constants. 
Dissociation constants for TBA1FAM and TBA2FAM were estimated as 1.820 nM and 0.867 nM, 
respectively. The fluorescence binding experiments herein conducted led to Kd values for these 
aptamers that are in accordance with the values reported in the literature, being in some cases 
even lower which indicates the sensitivity of the analytical method. 
The method used to develop the sensor was efficient because all samples dropped in the 
electrode showed a profile in which each concentration described a hThr voltamogramm. Thus, an 
aptamer-based electrochemical biosensor was developed for the detection of thrombin. Biotin 
modified TBA1 and TBA2 aptamers were immobilized on the surface of a screen-printed electrode, 
and the electrochemical analysis was conducted by cyclic voltammetry using [Fe(CN)6]4-/3- solution 
as a redox probe. The TBA2 electrochemical aptasensor was found to be sensitive to hThr with a 
linear response range from 0.5 to 50 nM and a LOD of 0.025 nM. 
TBA2 aptasensor could be viewed as an emerging device in the biomedical field and shows 
significant promise in the detection, analysis and monitoring of thrombin. However, there are some 
issues that need to be overcome. No effect was observed of interfering proteins in the response of 
the electrode, because the non-efficiency regeneration protocol. There are some issues to be 
improved such as the sensitivity, the sensor regeneration and the interferences which could lead to 
further research. 
      Future work 
58 
 
5. Future work: Improving and refining the techniques 
The fluorescence anisotropy technique used in this work can be further improved. An 
alternative dye can be used in these experiments, as for example the Cy5 dye. It has much longer 
excitation and emission wavelengths than 6-FAM. Longer excitation wavelength will cause less 
photobleaching and reduce the issues associated with the samples autofluorescence (Z. Cao, 
2002).  
Furthermore, regarding the aptasensor performance, some parameters should be reviewed 
to improve the sensor’s sensitivity and selectivity for thrombin detection. In particular, the 
parameters associated with the incubation of the protein in the electrode could be re-evaluated. As 
previously mentioned, some authors reported that the incubation temperature should not approach 
or surpass thrombin melting temperature since the aptamer cannot maintain its folded structure 
(Tang & Shafer, 2006), while other authors determined that low temperatures lead to more stable 
G-quarter structures of thrombin-aptamer, thus better detection (Eva  Baldrich et al., 2004; Zhao et 
al., 2011) .Therefore, a low incubation temperature (4◦C) could be tested  in the development of 
the thrombin aptasensor towards an improvement of its sensitivity. 
Finally, the advent of biosensors has allowed biomedical research and clinical diagnostics 
to develop upon the advantages of miniaturization, such as reduced sample volumes, faster 
reaction times, and the possibility of multiplexed detection (Ng & Chong, 2011). Multiplexing, 
meaning try to immobilize more than one specific aptamer in electrodes it is of particular 
importance, since the simultaneous detection of multiple targets at once can result in significant 
time savings, particularly for applications requiring high-throughput. Often, multiple targets must be 
detected in order to draw a meaningful conclusion in clinical diagnosis. Therefore, immobilizing 
both TBA1 and TBA2 aptamers in a single SPE could be an interesting and brainy approach to 
develop. 
  
       References 
59 
 
6. References 
 
Abe, K., Yoshida, W., & Ikebukuro, K. (2013). Electrochemical Biosensors Using Aptamers for 
Theranostics. Adv Biochem Eng Biotechnol.  
 
Alonso-Lomillo, M. A., Dominguez-Renedo, O., Matos, P., & Arcos-Martinez, M. J. (2009). 
Electrochemical determination of levetiracetam by screen-printed based biosensors. 
Bioelectrochemistry, 74(2), 306-309.  
Bai, J., Wei, H., Li, B., Song, L., Fang, L., Lv, Z., Wang, E. (2008). [Ru(bpy)2(dcbpy)NHS] 
labeling/aptamer-based biosensor for the detection of lysozyme by increasing sensitivity 
with gold nanoparticle amplification. Chem Asian J, 3(11), 1935-1941.  
 
Balamurugan, S., Obubuafo, A., Soper, S. a., & Spivak, D. a. (2008). Surface immobilization 
methods for aptamer diagnostic applications. Analytical and bioanalytical chemistry, 390, 
1009-1021.  
 
Baldrich, E., Restrepo, A., & O'Sullivan, C. K. (2004). Aptasensor development: elucidation of 
critical parameters for optimal aptamer performance. Anal Chem, 76(23), 7053-7063. 
Baldrich, E., Restrepo, A., & O′Sullivan, C. K. (2004). Aptasensor Development: Elucidation of 
Critical Parameters for Optimal Aptamer Performance. Clin Chem, 45, 1628-1650. 
  
Bang, G. S., Cho, S., & Kim, B. G. (2005). A novel electrochemical detection method for aptamer 
biosensors. Biosens Bioelectron, 21(6), 863-870. 
Beausoleil, M. S., Schulze, E. B., Goodale, D., Postenka, C. O., & Allan, A. L. (2011). Deletion of 
the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, 
proteolytic activity, tumorgenicity, and metastasis. BMC Cancer, 11(1), 25. 
  
Bock, P. E. (1992). Active-site-selective labeling of blood coagulation proteinases with fluorescence 
probes by the use of thioester peptide chloromethyl ketones. II. Properties of thrombin 
derivatives as reporters of prothrombin fragment 2 binding and specificity of the labeling 
approach for other proteinases. J Biol Chem, 267(21), 14974-14981.  
Bohunicky, B., & Mousa, S. A. (2010). Biosensors: the new wave in cancer diagnosis. 
Nanotechnology, Science and Applications, 1. 
 
Bunka, D. H., & Stockley, P. G. (2006). Aptamers come of age - at last. Nat Rev Microbiol, 4(8), 
588-596.  
Burmeister, P. E., Lewis, S. D., Silva, R. F., Preiss, J. R., Horwitz, L. R., Pendergrast, P. S., Keefe, A. 
D. (2005). Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem Biol, 12(1), 25-
33.  
 
       References 
60 
 
Cai, H., Lee, T. M.-H., & Hsing, I. M. (2006). Label-free protein recognition using an aptamer-based 
impedance measurement assay. Sensors and Actuators B: Chemical, 114(1), 433-437.  
 
Cao, D. X., Li, Z. J., Jiang, X. O., Lum, Y. L., Khin, E., Lee, N. P., Luk, J. M. (2012). Osteopontin as 
potential biomarker and therapeutic target in gastric and liver cancers. World J 
Gastroenterol, 18(30), 3923-3930.  
 
Cao, Z. (2002). Using Fluorescence Anisotropy for Sensitive Platelet-Derived Growth Factor 
Detection based on Molecular Aptamers. Master, Florida, University of Florida. 
    
Centi, S., Tombelli, S., Minunni, M., & Mascini, M. (2007). Aptamer-based detection of plasma 
proteins by an electrochemical assay coupled to magnetic beads. Anal Chem, 79, 1466-
1473.  
 
Chang, H., Tang, L., Wang, Y., Jiang, J., & Li, J. (2010). Graphene Fluorescence Resonance Energy 
Transfer Aptasensor for the Thrombin Detection. Anal Chem, 82, 2341-2346.  
 
Chen, H., Yuan, F., Wang, S., Xu, J., Zhang, Y., & Wang, L. (2013). Aptamer-based sensing for 
thrombin in red region via fluorescence resonant energy transfer between NaYF4:Yb,Er 
upconversion nanoparticles and gold nanorods. Biosens Bioelectron, 48, 19-25.  
 
Chen, L. J., Seo, J. H., Eller, M. J., Verkhoturov, S. V., Shah, S. S., Revzin, A., & Schweikert, E. A. 
(2011). Quantitative label-free characterization of avidin-biotin assemblies on silanized 
glass. Anal Chem, 83(18), 7173-7178.  
Chiu, T. C., & Huang, C. C. (2009). Aptamer-functionalized nano-biosensors. Sensors (Basel), 
9(12), 10356-10388.  
 
Cho, E. J., Collett, J. R., Szafranska, A. E., & Ellington, A. D. (2006). Optimization of aptamer 
microarray technology for multiple protein targets. Anal Chim Acta, 564(1), 82-90.  
 
Cho, E. J., Lee, J. W., & Ellington, A. D. (2009). Applications of aptamers as sensors. Annu Rev 
Anal Chem (Palo Alto Calif), 2, 241-264.  
D'Orazio, P. (2003). Biosensors in clinical chemistry. Clinica Chimica Acta, 334(1-2), 41-69. 
 
Daniels, J. S., & Pourmanda, N. (2007). Label-Free Impedance Biosensors Opportunities and 
Challenges. Electroanalysis, 19(12), 1239-1257.  
 
Diculescu, V. C., Chiorcea-Paquim, A. M., Eritja, R., & Oliveira-Brett, A. M. (2010). Thrombin-
Binding Aptamer Quadruplex Formation: AFM and Voltammetric Characterization. J Nucleic 
Acids, 2010.  
 
Ding, C., Ge, Y., & Lin, J. M. (2010). Aptamer based electrochemical assay for the determination of 
thrombin by using the amplification of the nanoparticles. Biosens Bioelectron, 25(6), 1290-
1294.  
 
Djordjevic, M. (2007). SELEX experiments new prospects, applications and data analysis in inferring 
regulatory pathways. Biomolecular Engineering, 24(2), 179-189.  
       References 
61 
 
Du, Y., Chen, C., Li, B., Zhou, M., Wang, E., & Dong, S. (2010). Layer-by-layer electrochemical 
biosensor with aptamer-appended active polyelectrolyte multilayer for sensitive protein 
determination. Biosens Bioelectron, 25(8), 1902-1907.  
 
Evtugyn, G. A., Porfireva, A. V., Hianik, T., Cheburova, M. S., & Budnikov, H. C. (2008). 
Potentiometric DNA Sensor Based on Electropolymerized Phenothiazines for Protein 
Detection. Electroanalysis, 20(12), 1300-1308.  
 
Fabre, B., Samorì, C., & Bianco, A. (2012). Immobilization of double functionalized carbon 
nanotubes on glassy carbon electrodes for the electrochemical sensing of the biotin–avidin 
affinity. Journal of Electroanalytical Chemistry, 665, 90-94.  
 
Fan, H., Li, H., Wang, Q., He, P., & Fang, Y. (2012). A host-guest-recognition-based electrochemical 
aptasensor for thrombin detection. Biosens Bioelectron, 35(1), 33-36.  
 
Feng, K., Sun, C., Kang, Y., Chen, J., Jiang, J.-H., Shen, G.-L., & Yu, R.-Q. (2008). Label-free 
electrochemical detection of nanomolar adenosine based on target-induced aptamer 
displacement. Electrochemistry Communications, 10(4), 531-535.  
 
Fisher, L. W., Torchia, D. A., Fohr, B., Young, M. F., & Fedarko, N. S. (2001). Flexible structures of 
SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun, 
280(2), 460-465.  
 
Frense, D., Kang, S., Schieke, K., Reich, P., Barthel, A., Pliquett, U., Beckmann, D. (2013). Label-
free impedimetric biosensor for thrombin using the thrombin-binding aptamer as receptor. 
Journal of Physics: Conference Series, 434, 012091.  
 
General, I. J., Dragomirova, R., & Meirovitch, H. (2011). New method for calculating the absolute 
free energy of binding: the effect of a mobile loop on the avidin/biotin complex. J Phys 
Chem B, 115(1), 168-175.  
 
Gokulrangan, G., Unruh, J. R., Holub, D. F., Ingram, B., Johnson, C. K., & Wilson, G. S. (2005). 
DNA Aptamer-Based Bioanalysis of IgE by Fluorescence Anisotropy. Analytical Chemistry, 
77(7), 1963-1970.  
 
Gopinath, S. C., Awazu, K., & Fujimaki, M. (2012). Waveguide-mode sensors as aptasensors. 
Sensors (Basel), 12(2), 2136-2151.  
Grieshaber, D., MacKenzie, R., Voros, J., & Reimhult, E. (2008). Electrochemical Biosensors - 
Sensor Principles and Architectures. Sensors, 8, 1400-1458.  
 
Guo, K.-T., Paul, A., Schichor, C., Ziemer, G., & Wendel, H. P. (2008). CELL-SELEX Novel 
Perspectives of Aptamer-Based Therapeutics. International Journal of Molecular Sciences, 
9, 668-678.  
 
Guo, K., Wang, Y., Chen, H., Ji, J., Zhang, S., Kong, J., & Liu, B. (2011). An aptamer–SWNT 
biosensor for sensitive detection of protein via mediated signal transduction. 
Electrochemistry Communications, 13(7), 707-710.  
       References 
62 
 
Guttridge, D. C. (1997). Thrombin Causes a Marked Delay in Skeletal Myogenesis That Correlates 
with the Delayed Expression of Myogenin and p21CIP1/WAF1. Journal of Biological 
Chemistry, 272(39), 24117-24120.  
 
Hamaguchi, N., Ellington, A., & Stanton, M. (2001). Aptamer beacons for the direct detection of 
proteins. Anal Biochem, 294(2), 126-131. 
Hamula, C., Guthrie, J., Zhang, H., Li, X., & Le, X. (2006). Selection and analytical applications of 
aptamers. TrAC Trends in Analytical Chemistry, 25(7), 681-691.  
 
Han, K., Liang, Z., & Zhou, N. (2010). Design strategies for aptamer-based biosensors. Sensors 
(Basel), 10(5), 4541-4557.  
 
Hansen, J. A., Wang, J., Kawde, A.-N., Xiang, Y., Gothelf, K. V., & Collins, G. (2006). Quantum-
Dot/Aptamer-Based Ultrasensitive Multi-Analyte Electrochemical Biosensor JACS articles, 
128, 2228-2229.  
He, P., Shen, L., Cao, Y., & Li, D. (2007). Ultrasensitive Electrochemical Detection of Proteins by 
Amplification of Aptamer-Nanoparticle Bio Bar Codes. Anal. Chem., 79, 8024-8029.  
 
Hianik, T., Ostatna, V., Sonlajtnerova, M., & Grman, I. (2007). Influence of ionic strength, pH and 
aptamer configuration for binding affinity to thrombin. Bioelectrochemistry, 70(1), 127-133.  
 
Hianik, T., Ostatna, V., Zajacova, Z., Stoikova, E., & Evtugyn, G. (2005). Detection of aptamer-
protein interactions using QCM and electrochemical indicator methods. Bioorg Med Chem 
Lett, 15(2), 291-295.  
 
Higashikawa, F., Eboshida, A., & Yokosaki, Y. (2007). Enhanced biological activity of polymeric 
osteopontin. FEBS Letters, 581, 2697-2701.  
 
Ho, H.-A., & Leclerc, M. (2004). Optical Sensors Based on Hybrid Aptamer/Conjugated Polymer 
Complexes. JACS articles, 126, 1384-1387.  
 
Hong, P., Li, W., & Li, J. (2012). Applications of aptasensors in clinical diagnostics. Sensors (Basel), 
12(2), 1181-1193. 
 
Huang, D. W., Niu, C. G., Qin, P. Z., Ruan, M., & Zeng, G. M. (2010). Time-resolved fluorescence 
aptamer-based sandwich assay for thrombin detection. Talanta, 83(1), 185-189.  
Huang, Y., Zhao, S., Chen, Z. F., Shi, M., Chen, J., & Liang, H. (2012). An amplified 
chemiluminescence aptasensor based on bi-resonance energy transfer on gold 
nanoparticles and exonuclease III-catalyzed target recycling. Chem Commun (Camb), 
48(97), 11877-11879. 
 
Ikebukuro, K., Kiyohara, C., & Sode, K. (2005). Novel electrochemical sensor system for protein 
using the aptamers in sandwich manner. Biosens Bioelectron, 20(10), 2168-2172.  
Jayasena, S. D. (1999). Aptamers An Emerging Class of Molecules That Rival Antibodies in Diagnostics, 
Clinical Chemistry, 45(9), 1628-1650.  
       References 
63 
 
Ji, J., Gan, J., Kong, J., Yang, P., Liu, B., & Ji, C. (2012). Electrochemical detection of the activities of 
thrombin and its inhibitor. Electrochemistry Communications, 16(1), 53-56.  
 
Jin, Y., Bai, J., & Li, H. (2010). Label-free protein recognition using aptamer-based fluorescence 
assay. Analyst, 135(7), 1731-1735.  
 
Justino, C. I. L., Rocha-Santos, T. A., & Duarte, A. C. (2010). Review of analytical figures of merit of 
sensors and biosensors in clinical applications. TrAC Trends in Analytical Chemistry, 
29(10), 1172-1183. 
 
Kadkol, S. S., Lin, A. Y., Barak, V., Kalickman, I., Leach, L., Valyi-Nagy, K., Pe'er, J. (2006). 
Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. 
Investigative ophthalmology & visual science, 47, 802-806.  
 
Kanwar, J. R., Roy, K., & Kanwar, R. K. (2011). Chimeric aptamers in cancer cell-targeted drug 
delivery. Crit Rev Biochem Mol Biol, 46(6), 459-477.  
Ke, H. L., Chang, L. L., Yang, S. F., Lin, H. H., Li, C. C., Wu, D. C., & Wu, W. J. (2011). 
Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial 
carcinoma. Urol Oncol, 29(6), 703-709. 
 
 
Keefe, A. D., & Cload, S. T. (2008). SELEX with modified nucleotides. Curr Opin Chem Biol, 12(4), 
448-456.  
Khezrian, S., Salimi, A., Teymourian, H., & Hallaj, R. (2013). Label-free electrochemical IgE 
aptasensor based on covalent attachment of aptamer onto multiwalled carbon 
nanotubes/ionic liquid/chitosan nanocomposite modified electrode. Biosens Bioelectron, 
43, 218-225.  
 
Kim, J.-h., Skates, S. J., Wong, K.-k., Feltmate, C. M., Berkowitz, R. S., Cramer, D. W., & Mok, S. C. 
(2002). Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer. 287, 1671-
1679.  
 
Kim, Y. S., Lee, S. J., & Gu, M. B. (2008). Electrochemical Aptamer-based Biosensors. 2, 175-182.  
Kulbachinskiy, A. V. (2007). Methods for selection of aptamers to protein targets. Biochemistry 
(Moscow), 72(13), 1505-1518.  
 
Kuralay, F., Campuzano, S., & Wang, J. (2012). Greatly extended storage stability of 
electrochemical DNA biosensors using ternary thiolated self-assembled monolayers. 
Talanta, 99, 155-160.  
 
Kwon, D., Jeong, H., & Chung, B. H. (2011). Label-free electrochemical detection of human alpha-
thrombin in blood serum using ferrocene-coated gold nanoparticles. Biosens Bioelectron, 
28(1), 454-458. 
 
Labuda, J., Brett, A. M. O., Evtugyn, G., Fojta, M., Mascini, M., Ozsoz, M., Wang, J. (2010). 
Electrochemical nucleic acid-based biosensors: Concepts, terms, and methodology (IUPAC 
Technical Report). Pure and Applied Chemistry, 82(5), 1161-1187.  
       References 
64 
 
Lee, J. A., Hwang, S., Lee, K.-C., Kwak, J., Park, S. I., & Lee, S. S. (2007). Pyrolyzed Carbon 
Biosensor for Aptamer-Protein Interactions Using Electrochemical Impedance Spectroscopy.  
 
Lee, J. H., Wernette, D. P., Yigit, M. V., Liu, J., Wang, Z., & Lu, Y. (2007). Site-Specific Control of 
Distances between Gold Nanoparticles Using Phosphorothioate Anchors on DNA and a 
Short Bifunctional Molecular Fastener. Angewandte Chemie, 119(47), 9164-9168.  
 
Lee, J. H., Yigit, M. V., Mazumdar, D., & Lu, Y. (2010). Molecular diagnostic and drug delivery 
agents based on aptamer-nanomaterial conjugates.Adv Drug Deliv Rev, 62(6), 592-605.  
Lee, J. O., So, H. M., Jeon, E. K., Chang, H., Won, K., & Kim, Y. H. (2008). Aptamers as molecular 
recognition elements for electrical nanobiosensors. Anal Bioanal Chem, 390(4), 1023-
1032.  
 
Lee, M., & Walt, D. R. (2000). A fiber-optic microarray biosensor using aptamers as receptors. Anal 
Biochem, 282(1), 142-146.  
 
Li, J., Orlandi, R., White, C. N., Rosenzweig, J., Zhao, J., Seregni, E., Chan, D. W. (2005). 
Independent validation of candidate breast cancer serum biomarkers identified by mass 
spectrometry. Clin Chem, 51(12), 2229-2235.  
 
Li, J. J., Fang, X., & Tan, W. (2002). Molecular Aptamer Beacons for Real-Time Protein Recognition. 
Biochem Biophys Res Commun, 292(1), 31-40.  
 
Li, W., Wang, K., Tan, W., Ma, C., & Yang, X. (2007). Aptamer-based analysis of angiogenin by 
fluorescence anisotropy. Analyst, 132(2), 107-113. 
 
Lin, S. F., Ding, T. J., Liu, J. T., Lee, C. C., Yang, T. H., Chen, W. Y., & Chang, J. Y. (2011). A 
guided mode resonance aptasensor for thrombin detection. Sensors (Basel), 11(9), 8953-
8965. 
 
Liu, S., Zhang, X., Luo, W., Wang, Z., Guo, X., Steigerwald, M. L., & Fang, X. (2011). Single-
Molecule Detection of Proteins Using Aptamer-Functionalized Molecular Electronic Devices. 
Angewandte Chemie.  
 
Liu, Y., Tuleouva, N., Ramanculov, E., & Revzin, A. (2010). Aptamer-based electrochemical 
biosensor for interferon gamma detection. Anal Chem, 82(19), 8131-8136.  
Liu, Z., Yuan, R., Chai, Y., Zhuo, Y., Hong, C., Yang, X., Qian, X. (2009). Highly sensitive, reusable 
electrochemical aptasensor for adenosine. Electrochimica Acta, 54(26), 6207-6211.  
 
Lord, S. J., Lei, W., Craft, P., Cawson, J. N., Morris, I., Walleser, S., Houssami, N. (2007). A 
systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition 
to mammography and ultrasound in screening young women at high risk of breast cancer. 
Eur J Cancer, 43(13), 1905-1917. 
Lu, Y., Zhu, N., Yu, P., & Mao, L. (2008). Aptamer-based electrochemical sensors that are not 
based on the target binding-induced conformational change of aptamers. Analyst, 133(9), 
1256-1260. 
       References 
65 
 
Macrì, A., Versaci, A., Lupo, G., Trimarchi, G., Tomasello, C., Loddo, S., Famulari, C. (2009). Role 
of osteopontin in breast cancer patients. 95, 48-52.  
 
Mairal, T., Ozalp, V. C., Lozano Sanchez, P., Mir, M., Katakis, I., & O'Sullivan, C. K. (2008). 
Aptamers: molecular tools for analytical applications. Anal Bioanal Chem, 390(4), 989-
1007.  
 
Mathelin, C., Cromer, A., Wendling, C., Tomasetto, C., & Rio, M. C. (2006). Serum biomarkers for 
detection of breast cancers: A prospective study. Breast Cancer Res Treat, 96(1), 83-90.  
 
Matsuura, M., Suzuki, T., & Saito, T. (2010). Osteopontin is a new target molecule for ovarian clear 
cell carcinoma therapy. Cancer Sci, 101(8), 1828-1833.  
 
Mayer, G. (2009). The Chemical Biology of Aptamers. Angewandte Chemie International Edition, 
48(15), 2672-2689.  
 
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005). 
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol, 23(36), 
9067-9072.  
 
Medley, C. D., Bamrungsap, S., Tan, W., & Smith, J. E. (2011). Aptamer-conjugated nanoparticles 
for cancer cell detection. Anal Chem, 83(3), 727-734.  
Mi, Z., Guo, H., & Kuo, P. C. (2009). Identification of osteopontin-dependent signaling pathways in 
a mouse model of human breast cancer. BMC Res Notes, 2, 119.  
 
Mi, Z., Guo, H., Russell, M. B., Liu, Y., Sullenger, B. a., & Kuo, P. C. (2009). RNA aptamer blockade 
of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. 
Molecular therapy : the journal of the American Society of Gene Therapy, 17, 153-161. 
  
Minunni, M., Tombelli, S., Gullotto, A., Luzi, E., & Mascini, M. (2004). Development of biosensors 
with aptamers as bio-recognition element: the case of HIV-1 Tat protein. Biosens 
Bioelectron, 20(6), 1149-1156.  
 
Mir, M., Vreeke, M., & Katakis, I. (2006). Different strategies to develop an electrochemical 
thrombin aptasensor. Electrochemistry Communications, 8(3), 505-511. 
 
Mirza, M., Shaughnessy, E., Hurley, J. K., Vanpatten, K. A., Pestano, G. A., He, B., & Weber, G. F. 
(2008). Osteopontin-c is a selective marker of breast cancer. Int J Cancer, 122(4), 889-
897.  
Misek, D. E., & Kim, E. H. (2011). Protein biomarkers for the early detection of breast cancer. Int J 
Proteomics, 2011, 343582.  
 
Neundlinger, I., Poturnayova, A., Karpisova, I., Rankl, C., Hinterdorfer, P., Snejdarkova, M., Ebner, 
A. (2011). Characterization of enhanced monovalent and bivalent thrombin DNA aptamer 
binding using single molecule force spectroscopy. Biophys J, 101(7), 1781-1787.  
 
       References 
66 
 
Ng, J. K.-K., & Chong, S. S. (2011). Multiplexing Capabilities of Biosensors for Clinical Diagnostics 
Biosensors for Health, Environment and Biosecurity. 
 
Numnuam, A., Chumbimuni-Torres, K. Y., Xiang, Y., Bash, R., Thavarungkul, P., Kanatharana, P., 
Bakker, E. (2008). Potentiometric Detection of DNA Hybridization. J Am Chem Soc., 
130(2), 410–411.  
 
Nutiu, R., & Li, Y. (2004). Structure-switching signaling aptamers: transducing molecular recognition 
into fluorescence signaling. Chemistry, 10(8), 1868-1876.  
 
O'Sullivan, C. K. (2002). Aptasensors--the future of biosensing? Anal Bioanal Chem, 372(1), 44-48.  
Ocana, C., Pacios, M., & del Valle, M. (2012). A reusable impedimetric aptasensor for detection of 
thrombin employing a graphite-epoxy composite electrode. Sensors (Basel), 12(3), 3037-
3048.  
 
Opstal-van Winden, A. W., Krop, E. J., Karedal, M. H., Gast, M. C., Lindh, C. H., Jeppsson, M. C., 
Vermeulen, R. C. (2011). Searching for early breast cancer biomarkers by serum protein 
profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer, 11, 381. 
 
Orita, T., Tomita, M., Harada, M., & Kato, K. (2012). Binding activity of avidin to the biotin within 
mesoporous silica materials for bioanalytical applications. Anal Biochem, 425(1), 1-9. 
  
Paborsky, L. R., N. McCurd, S., C. Griffin, L., J. Toole, J., & L. K. Leung, L. (1993). The Single-
stranded DNA Aptamer-binding Site of Human Thrombin. The Journalmof biological 
chemistry, 288(28), 20808-20811.  
 
Park, M. G., Oh, M. M., Yoon, J. H., Park, J. Y., Park, H. S., Moon, D. G., & Yoon, D. K. (2012). The 
value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in 
patients with bladder urothelial carcinoma: A prospective study. The Kaohsiung Journal of 
Medical Sciences.  
 
Phillips, J. A., Xu, Y., Xia, Z., Fan, Z. H., & Tan, W. (2009). Enrichment of cancer cells using 
aptamers immobilized on a microfluidic channel. Anal Chem, 81(3), 1033-1039.  
Potyrailo RA, Conrad RC, Ellington AD, & GM., H. (1998). Adapting selected nucleic acid ligands 
(aptamers) to biosensors. Anal Chem., 70(16), 3419-3425.  
 
Radi, A.-E. (2011). Electrochemical Aptamer-Based Biosensors: Recent Advances and Perspectives. 
International Journal of Electrochemistry, 2011, 1-17.  
 
Radi, A.-E., Sánchez, J. L. A., Baldrich, E., & O`Sullivan, C. K. (2005). Reagentless, Reusable, 
Ultrasensitive Electrochemical Molecular Beacon Aptasensoral JACS articles, 128, 117-124.  
 
Radi, A. E., Acero Sanchez, J. L., Baldrich, E., & O'Sullivan, C. K. (2005). Reusable impedimetric 
aptasensor. Anal Chem, 77(19), 6320-6323.  
 
       References 
67 
 
Radi, A. E., Acero Sanchez, J. L., Baldrich, E., & O'Sullivan, C. K. (2006). Reagentless, reusable, 
ultrasensitive electrochemical molecular beacon aptasensor. J Am Chem Soc, 128(1), 117-
124. 
 
Rangaswami, H., Bulbule, A., & Kundu, G. C. (2006). Osteopontin: role in cell signaling and cancer 
progression. Trends Cell Biol, 16(2), 79-87.  
Remmele, R. L. J., Enk, J. Z.-v., Dharmavaram, V., Balaban, D., Durst, M., Shoshitaishvili, A., & 
Rand, H. (2005). Scan-Rate-Dependent Melting Transitions of Interleukin-1 Receptor (Type 
II): Elucidation of Meaningful Thermodynamic and Kinetic Parameters of Aggregation 
Acquired from DSC Simulations. JACS articles, 127 8328-8339.  
 
Rittling, S. R., & Chambers, A. F. (2004). Role of osteopontin in tumour progression. Br J Cancer, 
90(10), 1877-1881.  
Rodrigues, L. R., Lopes, N., Sousa, B., Vieira, D., & Milanezi, F. (2009). Significance of Osteopontin 
Expression in Human Invasive Breast Tumour Stroma. 1-9.  
 
Rodrigues, L. R., Teixeira, J. a., Schmitt, F. L., Paulsson, M., & Lindmark-Mänsson, H. (2007). The 
role of osteopontin in tumor progression and metastasis in breast cancer. Cancer 
epidemiology, biomarkers & prevention : a publication of the American Association for 
Cancer Research, cosponsored by the American Society of Preventive Oncology, 16, 1087-
1097.  
 
Ronkainen, N. J., Halsall, H. B., & Heineman, W. R. (2010). Electrochemical biosensors. Chem Soc 
Rev, 39(5), 1747-1763.  
 
Rudland, P. S., Platt-higgins, A., El-tanani, M., Rudland, S. D. S., Barraclough, R., Winstanley, J. H. 
R., West, C. R. (2002). Prognostic Significance of the Metastasis-associated Protein 
Osteopontin in Human Breast Cancer 1. 3417-3427.  
 
Rusmini, F., Zhong, Z., & Feijen, J. (2007). Protein immobilization strategies for protein biochips. 
Biomacromolecules, 8, 1775-1789.  
 
Ryder, S. P., Recht, M. I., & Williamson, J. R. (2008). Quantitative analysis of protein-RNA 
interactions by gel mobility shift. Methods Mol Biol, 488, 99-115.  
Sadana, A., & Sadana, N. (2011). Handbook of Biosensors and Biosensor Kinetics.  
 
Sassolas, A., Blum, L. J., & Leca-Bouvier, B. D. (2009). Electrochemical Aptasensors. 
Electroanalysis, 21(11), 1237-1250.  
 
Sassolas, A., Blum, L. J., & Leca-Bouvier, B. D. (2011). Optical detection systems using 
immobilized aptamers. Biosens Bioelectron.  
 
Sassolas, A., Leca-Bouvier, B. D., & Blum, L. c. J. (2008). DNA Biosensors and Microarrays. 
Chemical Review, 108, 108-139.  
 
       References 
68 
 
Servais, E. L., Suzuki, K., Colovos, C., Rodriguez, L., Sima, C., Fleisher, M., Adusumilli, P. S. 
(2011). An in vivo platform for tumor biomarker assessment.PLoS One, 6(10), e26722.  
Shojaei, F., Scott, N., Kang, X., Lappin, P. B., Fitzgerald, A. A., Karlicek, S., Kraynov, E. (2012). 
Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung 
cancer. J Exp Clin Cancer Res, 31, 26.  
 
Song, K. M., Lee, S., & Ban, C. (2012). Aptamers and their biological applications. Sensors (Basel), 
12(1), 612-631. 
Song, S., Wang, L., Li, J., Fan, C., & Zhao, J. (2008). Aptamer-based biosensors. TrAC Trends in 
Analytical Chemistry, 27(2), 108-117.  
 
Song, S., Xu, H., & Fan, C. (2006). Potential diagnostic applications of biosensors: current and 
future directions. International Journal of Nanomedicine 1(4), 433–440.  
 
Sosic, A., Meneghello, A., Cretaio, E., & Gatto, B. (2011). Human thrombin detection through a 
sandwich aptamer microarray: interaction analysis in solution and in solid phase. Sensors 
(Basel), 11(10), 9426-9441.  
 
Stojanovic, M. N., Prada, P. D., & Landry, D. W. (2000). Fluorescent sensors based on aptamer 
self-assembly. J. Am. Chem. Soc., 122, 11547–11548.  
 
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007). SELEX--a (r)evolutionary method to generate 
high-affinity nucleic acid ligands. Biomol Eng, 24(4), 381-403. 
 
 Strehlitz, B., Nikolaus, N., & Stoltenburg, R. (2008). Protein Detection with Aptamer Biosensors. 
Sensors, 8(7), 4296-4307.  
 
Strehlitz, B., Reinemann, C., Linkorn, S., & Stoltenburg, R. (2011). Aptamers for pharmaceuticals 
and their application in environmental analytics. Bioanal Rev, 4(1), 1-30.  
 
Sultan, Y., Walsh, R., Monreal, C., & DeRosa, M. C. (2009). Preparation of functional aptamer films 
using layer-by-layer self-assembly. Biomacromolecules, 10(5), 1149-1154.  
 
Suprun, E., Shumyantseva, V., Bulko, T., Rachmetova, S., Rad'ko, S., Bodoev, N., & Archakov, A. 
(2008). Au-nanoparticles as an electrochemical sensing platform for aptamer-thrombin 
interaction. Biosens Bioelectron, 24(4), 831-836. 
Tang, C.-F., & Shafer, R. H. (2006). Engineering the Quadruplex Fold:  Nucleoside Conformation 
Determines Both Folding Topology and Molecularity in Guanine Quadruplexes. J. Am. 
Chem. Soc., 128(17), 5966–5973.  
 
Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide Inhibitors of Human Thrombin 
that Bind Distinct Epitopes. J. Mol. Biol. , 272, 688±698.  
 
Thevenot, D. R., Toth, K., Durst, R. A., & Wilson, G. S. (1999). Electrochemical biosensors 
Recommended definitions and classification ( Technical Report ). Pure Appl. Chem., 
71(12), 2333±2348.  
       References 
69 
 
Thévenot, D. R., Toth, K., Durst, R. A., & Wilson, G. S. (2001). Electrochemical biosensors: 
recommended definitions and classification. Biosensors & Bioelectronics 16, 121-131.  
 
Tombelli, S., Minunni, M., Luzi, E., & Mascini, M. (2005). Aptamer-based biosensors for the 
detection of HIV-1 Tat protein. Bioelectrochemistry, 67(2), 135-141.  
 
Tothill, I. E. (2009). Biosensors for cancer markers diagnosis.Semin Cell Dev Biol, 20(1), 55-62.  
Tran, D. T., Janssen, K. P., Pollet, J., Lammertyn, E., Anne, J., Van Schepdael, A., & Lammertyn, J. 
(2010). Selection and characterization of DNA aptamers for egg white lysozyme. Molecules, 
15(3), 1127-1140. 
 
Ulrich, H., & Wrenger, C. (2009). Disease-specific biomarker discovery by aptamers. Cytometry A, 
75(9), 727-733. 
Velasco-Garcia, M., & Missailidis, S. (2009). New trends in aptamer-based electrochemical 
biosensors. Gene Therapy and Molecular Biology, 13(1), 1-10.  
 
Wai, P. Y., & Kuo, P. C. (2004). The Role of Osteopontin in Tumor Metastasis. Journal of Surgical 
Research, 121, 228-241.  
 
Wai, P. Y., & Kuo, P. C. (2008). Osteopontin: regulation in tumor metastasis. Cancer Metastasis 
Rev, 27(1), 103-118.  
Wang, J. (2006). Electrochemical biosensors: towards point-of-care cancer diagnostics. Biosens 
Bioelectron, 21(10), 1887-1892. 
Wang, J., Chen, G., Jiang, H., Li, Z., & Wang, X. (2013). Advances in nano-scaled biosensors for 
biomedical applications. Analyst.  
 
Wang, P., Yang, Y., Hong, H., Zhang, Y., Cai, W., & Fang, D. (2011). Aptamers as Therapeutics in 
Cardiovascular Diseases. Curr Med Chem., 18(27), 4169-4174.  
 
Wang, W., Chen, C., Qian, M., & Zhao, X. S. (2008). Aptamer biosensor for protein detection using 
gold nanoparticles. Anal Biochem, 373(2), 213-219. 
Wang, X. Y., Gao, A., Lu, C. C., He, X. W., & Yin, X. B. (2013). An electrochemiluminescence 
aptasensor for thrombin using graphene oxide to immobilize the aptamer and the 
intercalated probe. Biosens Bioelectron, 48, 120-125. 
 
Weber, G. F., Lett, G. S., & Haubein, N. C. (2010). Osteopontin is a marker for cancer 
aggressiveness and patient survival. Br J Cancer, 103(6), 861-869.  
 
Wei, D., Bailey, M. J., Andrew, P., & Ryhanen, T. (2009). Electrochemical biosensors at the 
nanoscale. Lab Chip, 9(15), 2123-2131.  
 
Wei, F., Lillehoj, P. B., & Ho, C. M. (2010). DNA diagnostics: nanotechnology-enhanced 
electrochemical detection of nucleic acids. Pediatr Res, 67(5), 458-468.  
       References 
70 
 
Wu, Z. S., Zheng, F., Shen, G. L., & Yu, R. Q. (2009). A hairpin aptamer-based electrochemical 
biosensing platform for the sensitive detection of proteins. Biomaterials, 30(15), 2950-
2955. 
 
Xiao, Y., Lubin, A. A., Heeger, A. J., & Plaxco, K. W. (2005). Label-free electronic detection of 
thrombin in blood serum by using an aptamer-based sensor. Angew Chem Int Ed Engl, 
44(34), 5456-5459.  
Xie, S., & Walton, S. P. (2010). Development of a dual-aptamer-based multiplex protein biosensor. 
Biosens Bioelectron, 25(12), 2663-2668.  
Xie, S., Yuan, R., Chai, Y., Bai, L., Yuan, Y., & Wang, Y. (2012). Label-free electrochemical 
aptasensor for sensitive thrombin detection using layer-by-layer self-assembled multilayers 
with toluidine blue-graphene composites and gold nanoparticles. Talanta, 98, 7-13.  
 
Xie, W. Z., Leibl, M., Clark, M. R., Dohrmann, P., Kunze, T., & Gieseler, F. (2005). Activation of the 
coagulation system in cancerogenesis and metastasation. Biomed Pharmacother, 59(3), 
70-75.  
 
Xu, D., Xu, D., Yu, X., Liu, Z., He, W., & Ma, Z. (2005). Label-free Electrochemical Detection for 
aptamer-Based Array Electrodes. Anal Chem, 77, 5107-5113.  
 
Xu, Y., Cheng, G., He, P., & Fang, Y. (2009). A Review: Electrochemical Aptasensors with Various 
Detection Strategies. Electroanalysis, 21(11), 1251-1259.  
 
Xu, Y., Yang, L., Ye, X., He, P., & Fang, Y. (2006). An Aptamer-Based Protein Biosensor by 
Detecting the Amplified Impedance Signal. Electroanalysis, 18(15), 1449-1456.  
 
Yan, F., Wang, F., & Chen, Z. (2011). Aptamer-based electrochemical biosensor for label-free 
voltammetric detection of thrombin and adenosine. Sensors and Actuators B: Chemical, 
160(1), 1380-1385.  
 
Zhang, Y.-L., Huang, Y., Jiang, J.-H., Shen, G.-L., & Yu, R.-Q. (2007). Electrochemical Aptasensor 
Based on Proximity-Dependent Surface Hybridization Assay for Single-Step, Reusable, 
Sensitive Protein Detection. JACS articles, 129, 15448-15449.  
 
Zhao, J., Zhang, Y., Li, H., Wen, Y., Fan, X., Lin, F., Yao, S. (2011). Ultrasensitive electrochemical 
aptasensor for thrombin based on the amplification of aptamer-AuNPs-HRP conjugates. 
Biosens Bioelectron, 26(5), 2297-2303.  
 
Zhao(a), J., He, X., Bo, B., Liu, X., Yin, Y., & Li, G. (2012). A "signal-on" electrochemical aptasensor 
for simultaneous detection of two tumor markers. Biosens Bioelectron, 34(1), 249-252.  
 
Zhou, L., Wang, M.-H., Wang, J.-P., & Ye, Z.-Z. (2011). Application of Biosensor Surface 
Immobilization Methods for Aptamer. Chinese Journal of Analytical Chemistry, 39, 432-
438.  
 
Zhou, Y., Chiu, C. W., & Liang, H. (2012). Interfacial structures and properties of organic materials 
for biosensors: an overview. Sensors (Basel), 12(11), 15036-15062.  
       References 
71 
 
Zou, M., Chen, Y., Xu, X., Huang, H., Liu, F., & Li, N. (2012). The homogeneous fluorescence 
anisotropic sensing of salivary lysozyme using the 6-carboxyfluorescein-labeled DNA 
aptamer. Biosens Bioelectron, 32(1), 148-154.  
Zuo, X., Xiao, Y., & Plaxco, K. W. (2009). High specificity, electrochemical sandwich assays based 
on single aptamer sequences and suitable for the direct detection of small-molecule targets 
in blood and other complex matrices. J. Am. Chem. Soc., 131, 6944–6945.  
 
 
